STUDYID,SUBJID,USUBJID,AGE,STR01,STR01N,STR01L,STR02,STR02N,STR02L,TRT01P,TRT01PN,PARAM,PARAMCD,AVAL,CNSR,CNSDTDSC,DCTREAS
PSIVISSIG0002,1,PSIVISSIG0002_1,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2,PSIVISSIG0002_2,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1101,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,3,PSIVISSIG0002_3,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1771,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,4,PSIVISSIG0002_4,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,289,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,5,PSIVISSIG0002_5,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,6,PSIVISSIG0002_6,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,7,PSIVISSIG0002_7,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,8,PSIVISSIG0002_8,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1330,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,9,PSIVISSIG0002_9,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1411,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,10,PSIVISSIG0002_10,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,11,PSIVISSIG0002_11,65,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,12,PSIVISSIG0002_12,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,309,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,13,PSIVISSIG0002_13,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,14,PSIVISSIG0002_14,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1501,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,15,PSIVISSIG0002_15,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,21,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,16,PSIVISSIG0002_16,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,151,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,17,PSIVISSIG0002_17,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,124,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,18,PSIVISSIG0002_18,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,560,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,19,PSIVISSIG0002_19,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,20,PSIVISSIG0002_20,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,179,1,Censored at the last contact date,DEATH
PSIVISSIG0002,21,PSIVISSIG0002_21,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,22,PSIVISSIG0002_22,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1205,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,23,PSIVISSIG0002_23,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1093,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,24,PSIVISSIG0002_24,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,680,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,25,PSIVISSIG0002_25,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,28,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,26,PSIVISSIG0002_26,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,27,PSIVISSIG0002_27,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,28,PSIVISSIG0002_28,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,994,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,PSIVISSIG0002_29,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,30,PSIVISSIG0002_30,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,31,PSIVISSIG0002_31,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,32,PSIVISSIG0002_32,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,33,PSIVISSIG0002_33,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,34,PSIVISSIG0002_34,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,35,PSIVISSIG0002_35,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,851,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,36,PSIVISSIG0002_36,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1593,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,37,PSIVISSIG0002_37,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,311,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,38,PSIVISSIG0002_38,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,39,PSIVISSIG0002_39,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,40,PSIVISSIG0002_40,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,655,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,41,PSIVISSIG0002_41,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,42,PSIVISSIG0002_42,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,213,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,43,PSIVISSIG0002_43,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,111,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,44,PSIVISSIG0002_44,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,45,PSIVISSIG0002_45,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,163,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,46,PSIVISSIG0002_46,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,224,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,47,PSIVISSIG0002_47,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,434,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,48,PSIVISSIG0002_48,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,267,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,49,PSIVISSIG0002_49,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,491,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,50,PSIVISSIG0002_50,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,0,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,51,PSIVISSIG0002_51,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,52,PSIVISSIG0002_52,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,53,PSIVISSIG0002_53,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,147,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,54,PSIVISSIG0002_54,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,734,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,55,PSIVISSIG0002_55,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,695,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,56,PSIVISSIG0002_56,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,985,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,57,PSIVISSIG0002_57,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,18,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,58,PSIVISSIG0002_58,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,27,1,Censored at the last contact date,DEATH
PSIVISSIG0002,59,PSIVISSIG0002_59,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,860,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,60,PSIVISSIG0002_60,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,61,PSIVISSIG0002_61,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1125,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,62,PSIVISSIG0002_62,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,324,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,63,PSIVISSIG0002_63,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,890,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,64,PSIVISSIG0002_64,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,426,1,Censored at the last contact date,DEATH
PSIVISSIG0002,65,PSIVISSIG0002_65,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,66,PSIVISSIG0002_66,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1726,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,67,PSIVISSIG0002_67,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,140,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,68,PSIVISSIG0002_68,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,147,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,69,PSIVISSIG0002_69,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1603,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,70,PSIVISSIG0002_70,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,71,PSIVISSIG0002_71,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,819,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,72,PSIVISSIG0002_72,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,PSIVISSIG0002_73,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,74,PSIVISSIG0002_74,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,75,PSIVISSIG0002_75,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1405,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,76,PSIVISSIG0002_76,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,77,PSIVISSIG0002_77,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,785,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,78,PSIVISSIG0002_78,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,79,PSIVISSIG0002_79,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1062,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,80,PSIVISSIG0002_80,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,81,PSIVISSIG0002_81,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,82,PSIVISSIG0002_82,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,135,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,83,PSIVISSIG0002_83,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,84,PSIVISSIG0002_84,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1153,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,85,PSIVISSIG0002_85,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,396,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,86,PSIVISSIG0002_86,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1691,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,87,PSIVISSIG0002_87,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,88,PSIVISSIG0002_88,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,731,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,PSIVISSIG0002_89,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,657,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,90,PSIVISSIG0002_90,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,808,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,91,PSIVISSIG0002_91,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,92,PSIVISSIG0002_92,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,71,1,Censored at the last contact date,DEATH
PSIVISSIG0002,93,PSIVISSIG0002_93,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1497,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,94,PSIVISSIG0002_94,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,977,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,95,PSIVISSIG0002_95,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,96,PSIVISSIG0002_96,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,97,PSIVISSIG0002_97,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,842,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,98,PSIVISSIG0002_98,24,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,25,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,99,PSIVISSIG0002_99,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,237,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,100,PSIVISSIG0002_100,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,101,PSIVISSIG0002_101,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1015,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,102,PSIVISSIG0002_102,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,103,PSIVISSIG0002_103,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,104,PSIVISSIG0002_104,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1326,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,105,PSIVISSIG0002_105,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1546,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,106,PSIVISSIG0002_106,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,79,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,107,PSIVISSIG0002_107,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,744,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,108,PSIVISSIG0002_108,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1249,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,109,PSIVISSIG0002_109,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,110,PSIVISSIG0002_110,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1741,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,111,PSIVISSIG0002_111,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,631,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,112,PSIVISSIG0002_112,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,484,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,113,PSIVISSIG0002_113,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,114,PSIVISSIG0002_114,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,626,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,115,PSIVISSIG0002_115,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,116,PSIVISSIG0002_116,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,274,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,117,PSIVISSIG0002_117,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,307,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,118,PSIVISSIG0002_118,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1207,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,PSIVISSIG0002_119,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,120,PSIVISSIG0002_120,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,121,PSIVISSIG0002_121,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,PSIVISSIG0002_122,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,123,PSIVISSIG0002_123,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,124,PSIVISSIG0002_124,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,125,PSIVISSIG0002_125,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,304,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,126,PSIVISSIG0002_126,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,127,PSIVISSIG0002_127,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,128,PSIVISSIG0002_128,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,129,PSIVISSIG0002_129,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,561,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,130,PSIVISSIG0002_130,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,779,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,131,PSIVISSIG0002_131,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1050,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,132,PSIVISSIG0002_132,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,639,1,Censored at the last contact date,DEATH
PSIVISSIG0002,133,PSIVISSIG0002_133,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,828,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,134,PSIVISSIG0002_134,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,135,PSIVISSIG0002_135,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,679,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,136,PSIVISSIG0002_136,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,137,PSIVISSIG0002_137,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,138,PSIVISSIG0002_138,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,139,PSIVISSIG0002_139,65,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,140,PSIVISSIG0002_140,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1622,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,141,PSIVISSIG0002_141,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,142,PSIVISSIG0002_142,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,143,PSIVISSIG0002_143,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,299,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,144,PSIVISSIG0002_144,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,145,PSIVISSIG0002_145,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,618,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,146,PSIVISSIG0002_146,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,72,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,147,PSIVISSIG0002_147,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,148,PSIVISSIG0002_148,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,228,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,149,PSIVISSIG0002_149,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,653,1,Censored at the last contact date,DEATH
PSIVISSIG0002,150,PSIVISSIG0002_150,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,86,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,151,PSIVISSIG0002_151,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,739,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,152,PSIVISSIG0002_152,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,153,PSIVISSIG0002_153,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,154,PSIVISSIG0002_154,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1083,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,155,PSIVISSIG0002_155,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,156,PSIVISSIG0002_156,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,273,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,157,PSIVISSIG0002_157,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,665,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,158,PSIVISSIG0002_158,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,159,PSIVISSIG0002_159,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,970,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,160,PSIVISSIG0002_160,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,416,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,161,PSIVISSIG0002_161,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,688,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,PSIVISSIG0002_162,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1053,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,163,PSIVISSIG0002_163,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,164,PSIVISSIG0002_164,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,264,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,165,PSIVISSIG0002_165,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,181,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,166,PSIVISSIG0002_166,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,735,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,167,PSIVISSIG0002_167,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,411,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,168,PSIVISSIG0002_168,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,169,PSIVISSIG0002_169,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,170,PSIVISSIG0002_170,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,13,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,171,PSIVISSIG0002_171,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,642,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,172,PSIVISSIG0002_172,64,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,207,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,173,PSIVISSIG0002_173,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,120,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,174,PSIVISSIG0002_174,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,175,PSIVISSIG0002_175,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1497,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,176,PSIVISSIG0002_176,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1606,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,177,PSIVISSIG0002_177,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,968,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,178,PSIVISSIG0002_178,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,179,PSIVISSIG0002_179,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,502,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,180,PSIVISSIG0002_180,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,181,PSIVISSIG0002_181,17,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,PSIVISSIG0002_182,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,183,PSIVISSIG0002_183,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,223,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,184,PSIVISSIG0002_184,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1260,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,185,PSIVISSIG0002_185,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,186,PSIVISSIG0002_186,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,929,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,187,PSIVISSIG0002_187,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,188,PSIVISSIG0002_188,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,189,PSIVISSIG0002_189,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,190,PSIVISSIG0002_190,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,191,PSIVISSIG0002_191,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,192,PSIVISSIG0002_192,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,193,PSIVISSIG0002_193,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,194,PSIVISSIG0002_194,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,195,PSIVISSIG0002_195,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,332,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,196,PSIVISSIG0002_196,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,986,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,197,PSIVISSIG0002_197,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,198,PSIVISSIG0002_198,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1623,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,199,PSIVISSIG0002_199,21,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,930,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,PSIVISSIG0002_200,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,201,PSIVISSIG0002_201,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1534,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,202,PSIVISSIG0002_202,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,203,PSIVISSIG0002_203,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,204,PSIVISSIG0002_204,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,953,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,205,PSIVISSIG0002_205,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,206,PSIVISSIG0002_206,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,PSIVISSIG0002_207,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,548,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,208,PSIVISSIG0002_208,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,209,PSIVISSIG0002_209,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1282,1,Censored at the last contact date,DEATH
PSIVISSIG0002,210,PSIVISSIG0002_210,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,498,1,Censored at the last contact date,DEATH
PSIVISSIG0002,211,PSIVISSIG0002_211,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,212,PSIVISSIG0002_212,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1134,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,213,PSIVISSIG0002_213,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,81,1,Censored at the last contact date,DEATH
PSIVISSIG0002,214,PSIVISSIG0002_214,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,125,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,215,PSIVISSIG0002_215,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,216,PSIVISSIG0002_216,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,80,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,217,PSIVISSIG0002_217,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1002,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,218,PSIVISSIG0002_218,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,571,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,219,PSIVISSIG0002_219,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,220,PSIVISSIG0002_220,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,212,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,221,PSIVISSIG0002_221,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1432,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,222,PSIVISSIG0002_222,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,125,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,223,PSIVISSIG0002_223,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,487,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,224,PSIVISSIG0002_224,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1645,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,225,PSIVISSIG0002_225,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,190,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,226,PSIVISSIG0002_226,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,227,PSIVISSIG0002_227,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,228,PSIVISSIG0002_228,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,229,PSIVISSIG0002_229,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1572,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,230,PSIVISSIG0002_230,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,769,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,231,PSIVISSIG0002_231,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,232,PSIVISSIG0002_232,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1104,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,233,PSIVISSIG0002_233,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,234,PSIVISSIG0002_234,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,235,PSIVISSIG0002_235,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,236,PSIVISSIG0002_236,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,817,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,237,PSIVISSIG0002_237,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,238,PSIVISSIG0002_238,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,239,PSIVISSIG0002_239,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,184,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,240,PSIVISSIG0002_240,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,241,PSIVISSIG0002_241,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,242,PSIVISSIG0002_242,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,243,PSIVISSIG0002_243,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,941,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,244,PSIVISSIG0002_244,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,245,PSIVISSIG0002_245,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,246,PSIVISSIG0002_246,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,247,PSIVISSIG0002_247,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,484,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,248,PSIVISSIG0002_248,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,249,PSIVISSIG0002_249,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,603,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,250,PSIVISSIG0002_250,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,251,PSIVISSIG0002_251,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,998,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,252,PSIVISSIG0002_252,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,253,PSIVISSIG0002_253,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1748,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,254,PSIVISSIG0002_254,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,752,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,255,PSIVISSIG0002_255,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,256,PSIVISSIG0002_256,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,257,PSIVISSIG0002_257,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,487,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,258,PSIVISSIG0002_258,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,259,PSIVISSIG0002_259,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,436,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,260,PSIVISSIG0002_260,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,31,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,261,PSIVISSIG0002_261,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,281,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,262,PSIVISSIG0002_262,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,892,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,263,PSIVISSIG0002_263,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1112,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,264,PSIVISSIG0002_264,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,265,PSIVISSIG0002_265,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,266,PSIVISSIG0002_266,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,267,PSIVISSIG0002_267,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1308,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,268,PSIVISSIG0002_268,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,269,PSIVISSIG0002_269,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,287,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,270,PSIVISSIG0002_270,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,271,PSIVISSIG0002_271,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,200,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,272,PSIVISSIG0002_272,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,273,PSIVISSIG0002_273,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,274,PSIVISSIG0002_274,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,275,PSIVISSIG0002_275,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1342,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,276,PSIVISSIG0002_276,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,115,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,277,PSIVISSIG0002_277,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,278,PSIVISSIG0002_278,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,714,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,279,PSIVISSIG0002_279,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,753,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,280,PSIVISSIG0002_280,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,33,1,Censored at the last contact date,DEATH
PSIVISSIG0002,281,PSIVISSIG0002_281,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,552,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,282,PSIVISSIG0002_282,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,283,PSIVISSIG0002_283,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,284,PSIVISSIG0002_284,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,285,PSIVISSIG0002_285,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,286,PSIVISSIG0002_286,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,287,PSIVISSIG0002_287,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1677,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,288,PSIVISSIG0002_288,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,289,PSIVISSIG0002_289,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,928,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,290,PSIVISSIG0002_290,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1488,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,291,PSIVISSIG0002_291,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,621,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,292,PSIVISSIG0002_292,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,293,PSIVISSIG0002_293,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,294,PSIVISSIG0002_294,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,295,PSIVISSIG0002_295,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,296,PSIVISSIG0002_296,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,297,PSIVISSIG0002_297,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,402,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,298,PSIVISSIG0002_298,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,275,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,299,PSIVISSIG0002_299,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,300,PSIVISSIG0002_300,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,301,PSIVISSIG0002_301,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,302,PSIVISSIG0002_302,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,303,PSIVISSIG0002_303,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1644,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,304,PSIVISSIG0002_304,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,882,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,305,PSIVISSIG0002_305,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,306,PSIVISSIG0002_306,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,763,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,307,PSIVISSIG0002_307,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1283,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,308,PSIVISSIG0002_308,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,309,PSIVISSIG0002_309,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,243,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,310,PSIVISSIG0002_310,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,311,PSIVISSIG0002_311,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,102,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,312,PSIVISSIG0002_312,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,313,PSIVISSIG0002_313,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,153,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,314,PSIVISSIG0002_314,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,315,PSIVISSIG0002_315,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,316,PSIVISSIG0002_316,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,91,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,317,PSIVISSIG0002_317,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,811,1,Censored at the last contact date,DEATH
PSIVISSIG0002,318,PSIVISSIG0002_318,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,653,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,319,PSIVISSIG0002_319,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,320,PSIVISSIG0002_320,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,321,PSIVISSIG0002_321,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,322,PSIVISSIG0002_322,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,759,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,323,PSIVISSIG0002_323,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,324,PSIVISSIG0002_324,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,325,PSIVISSIG0002_325,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,326,PSIVISSIG0002_326,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,327,PSIVISSIG0002_327,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,801,1,Censored at the last contact date,DEATH
PSIVISSIG0002,328,PSIVISSIG0002_328,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,329,PSIVISSIG0002_329,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,330,PSIVISSIG0002_330,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,77,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,331,PSIVISSIG0002_331,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,266,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,332,PSIVISSIG0002_332,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,333,PSIVISSIG0002_333,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,334,PSIVISSIG0002_334,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,335,PSIVISSIG0002_335,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,336,PSIVISSIG0002_336,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,5,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,337,PSIVISSIG0002_337,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,338,PSIVISSIG0002_338,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,794,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,339,PSIVISSIG0002_339,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1089,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,PSIVISSIG0002_340,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,341,PSIVISSIG0002_341,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,480,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,342,PSIVISSIG0002_342,63,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1148,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,343,PSIVISSIG0002_343,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,601,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,344,PSIVISSIG0002_344,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,345,PSIVISSIG0002_345,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,346,PSIVISSIG0002_346,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1136,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,347,PSIVISSIG0002_347,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,348,PSIVISSIG0002_348,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,349,PSIVISSIG0002_349,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,350,PSIVISSIG0002_350,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,825,1,Censored at the last contact date,DEATH
PSIVISSIG0002,351,PSIVISSIG0002_351,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1454,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,352,PSIVISSIG0002_352,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,758,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,353,PSIVISSIG0002_353,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1023,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,354,PSIVISSIG0002_354,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,355,PSIVISSIG0002_355,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,356,PSIVISSIG0002_356,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,229,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,357,PSIVISSIG0002_357,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,345,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,358,PSIVISSIG0002_358,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,359,PSIVISSIG0002_359,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,368,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,360,PSIVISSIG0002_360,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1025,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,361,PSIVISSIG0002_361,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,766,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,362,PSIVISSIG0002_362,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,40,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,363,PSIVISSIG0002_363,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,364,PSIVISSIG0002_364,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,365,PSIVISSIG0002_365,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,366,PSIVISSIG0002_366,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,367,PSIVISSIG0002_367,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,250,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,368,PSIVISSIG0002_368,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,30,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,369,PSIVISSIG0002_369,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,370,PSIVISSIG0002_370,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1264,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,371,PSIVISSIG0002_371,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,347,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,372,PSIVISSIG0002_372,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,178,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,373,PSIVISSIG0002_373,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,374,PSIVISSIG0002_374,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,441,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,375,PSIVISSIG0002_375,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,171,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,376,PSIVISSIG0002_376,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,377,PSIVISSIG0002_377,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,147,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,378,PSIVISSIG0002_378,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,21,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,379,PSIVISSIG0002_379,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,380,PSIVISSIG0002_380,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,381,PSIVISSIG0002_381,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,755,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,382,PSIVISSIG0002_382,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,383,PSIVISSIG0002_383,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,384,PSIVISSIG0002_384,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,PSIVISSIG0002_385,26,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,386,PSIVISSIG0002_386,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,387,PSIVISSIG0002_387,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,136,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,388,PSIVISSIG0002_388,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,711,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,389,PSIVISSIG0002_389,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,390,PSIVISSIG0002_390,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,572,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,391,PSIVISSIG0002_391,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,141,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,392,PSIVISSIG0002_392,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1247,1,Censored at the last contact date,DEATH
PSIVISSIG0002,393,PSIVISSIG0002_393,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,401,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,394,PSIVISSIG0002_394,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,11,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,395,PSIVISSIG0002_395,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,396,PSIVISSIG0002_396,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1688,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,397,PSIVISSIG0002_397,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,398,PSIVISSIG0002_398,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,399,PSIVISSIG0002_399,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1369,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,400,PSIVISSIG0002_400,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,512,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,401,PSIVISSIG0002_401,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,402,PSIVISSIG0002_402,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,524,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,403,PSIVISSIG0002_403,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,70,1,Censored at the last contact date,DEATH
PSIVISSIG0002,404,PSIVISSIG0002_404,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,405,PSIVISSIG0002_405,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1062,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,406,PSIVISSIG0002_406,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,407,PSIVISSIG0002_407,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,408,PSIVISSIG0002_408,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,698,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,409,PSIVISSIG0002_409,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,410,PSIVISSIG0002_410,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,411,PSIVISSIG0002_411,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1003,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,412,PSIVISSIG0002_412,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,413,PSIVISSIG0002_413,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,15,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,414,PSIVISSIG0002_414,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,415,PSIVISSIG0002_415,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,416,PSIVISSIG0002_416,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,888,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,417,PSIVISSIG0002_417,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,907,1,Censored at the last contact date,DEATH
PSIVISSIG0002,418,PSIVISSIG0002_418,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1637,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,419,PSIVISSIG0002_419,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,420,PSIVISSIG0002_420,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,427,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,421,PSIVISSIG0002_421,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,391,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,422,PSIVISSIG0002_422,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1319,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,423,PSIVISSIG0002_423,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,424,PSIVISSIG0002_424,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,425,PSIVISSIG0002_425,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,894,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,426,PSIVISSIG0002_426,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,427,PSIVISSIG0002_427,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,807,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,428,PSIVISSIG0002_428,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,429,PSIVISSIG0002_429,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,226,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,430,PSIVISSIG0002_430,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,934,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,431,PSIVISSIG0002_431,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,520,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,432,PSIVISSIG0002_432,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,416,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,433,PSIVISSIG0002_433,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,471,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,434,PSIVISSIG0002_434,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,834,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,435,PSIVISSIG0002_435,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,995,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,436,PSIVISSIG0002_436,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,437,PSIVISSIG0002_437,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,438,PSIVISSIG0002_438,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,243,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,439,PSIVISSIG0002_439,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,639,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,440,PSIVISSIG0002_440,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,176,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,441,PSIVISSIG0002_441,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,442,PSIVISSIG0002_442,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,443,PSIVISSIG0002_443,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,703,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,444,PSIVISSIG0002_444,66,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,445,PSIVISSIG0002_445,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,446,PSIVISSIG0002_446,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,210,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,447,PSIVISSIG0002_447,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1046,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,448,PSIVISSIG0002_448,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,489,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,449,PSIVISSIG0002_449,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,450,PSIVISSIG0002_450,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,451,PSIVISSIG0002_451,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,452,PSIVISSIG0002_452,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,536,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,453,PSIVISSIG0002_453,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,454,PSIVISSIG0002_454,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1097,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,455,PSIVISSIG0002_455,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,100,1,Censored at the last contact date,DEATH
PSIVISSIG0002,456,PSIVISSIG0002_456,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,692,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,457,PSIVISSIG0002_457,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,458,PSIVISSIG0002_458,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,459,PSIVISSIG0002_459,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,460,PSIVISSIG0002_460,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,384,1,Censored at the last contact date,DEATH
PSIVISSIG0002,461,PSIVISSIG0002_461,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1335,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,462,PSIVISSIG0002_462,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,463,PSIVISSIG0002_463,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Censored at the last contact date,DEATH
PSIVISSIG0002,464,PSIVISSIG0002_464,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,40,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,465,PSIVISSIG0002_465,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,409,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,466,PSIVISSIG0002_466,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,853,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,467,PSIVISSIG0002_467,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,468,PSIVISSIG0002_468,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,253,1,Censored at the last contact date,DEATH
PSIVISSIG0002,469,PSIVISSIG0002_469,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,470,PSIVISSIG0002_470,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,611,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,471,PSIVISSIG0002_471,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,472,PSIVISSIG0002_472,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,726,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,473,PSIVISSIG0002_473,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,167,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,474,PSIVISSIG0002_474,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1465,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,475,PSIVISSIG0002_475,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,351,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,476,PSIVISSIG0002_476,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1710,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,477,PSIVISSIG0002_477,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1664,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,478,PSIVISSIG0002_478,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,479,PSIVISSIG0002_479,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,480,PSIVISSIG0002_480,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,22,1,Censored at the last contact date,DEATH
PSIVISSIG0002,481,PSIVISSIG0002_481,59,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,482,PSIVISSIG0002_482,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,119,1,Censored at the last contact date,DEATH
PSIVISSIG0002,483,PSIVISSIG0002_483,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,51,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,484,PSIVISSIG0002_484,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,729,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,485,PSIVISSIG0002_485,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,486,PSIVISSIG0002_486,31,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,487,PSIVISSIG0002_487,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,488,PSIVISSIG0002_488,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,489,PSIVISSIG0002_489,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1098,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,PSIVISSIG0002_490,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,282,1,Censored at the last contact date,DEATH
PSIVISSIG0002,491,PSIVISSIG0002_491,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,492,PSIVISSIG0002_492,25,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,493,PSIVISSIG0002_493,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,494,PSIVISSIG0002_494,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,495,PSIVISSIG0002_495,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,496,PSIVISSIG0002_496,19,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,497,PSIVISSIG0002_497,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,90,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,498,PSIVISSIG0002_498,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,499,PSIVISSIG0002_499,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1030,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,500,PSIVISSIG0002_500,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1141,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,501,PSIVISSIG0002_501,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,502,PSIVISSIG0002_502,13,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,627,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,503,PSIVISSIG0002_503,28,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1069,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,504,PSIVISSIG0002_504,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,505,PSIVISSIG0002_505,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,506,PSIVISSIG0002_506,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,590,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,507,PSIVISSIG0002_507,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,508,PSIVISSIG0002_508,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1078,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,509,PSIVISSIG0002_509,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,510,PSIVISSIG0002_510,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,511,PSIVISSIG0002_511,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,512,PSIVISSIG0002_512,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,454,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,513,PSIVISSIG0002_513,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,514,PSIVISSIG0002_514,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,515,PSIVISSIG0002_515,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,516,PSIVISSIG0002_516,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,517,PSIVISSIG0002_517,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,518,PSIVISSIG0002_518,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,499,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,519,PSIVISSIG0002_519,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,971,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,520,PSIVISSIG0002_520,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1760,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,521,PSIVISSIG0002_521,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,522,PSIVISSIG0002_522,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,903,1,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,523,PSIVISSIG0002_523,19,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,524,PSIVISSIG0002_524,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,525,PSIVISSIG0002_525,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,734,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,526,PSIVISSIG0002_526,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,774,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,527,PSIVISSIG0002_527,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,528,PSIVISSIG0002_528,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,223,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,529,PSIVISSIG0002_529,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,530,PSIVISSIG0002_530,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1071,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,531,PSIVISSIG0002_531,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,457,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,PSIVISSIG0002_532,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,533,PSIVISSIG0002_533,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,534,PSIVISSIG0002_534,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,535,PSIVISSIG0002_535,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,536,PSIVISSIG0002_536,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,746,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,537,PSIVISSIG0002_537,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,538,PSIVISSIG0002_538,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1525,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,539,PSIVISSIG0002_539,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,492,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,PSIVISSIG0002_540,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,455,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,541,PSIVISSIG0002_541,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,542,PSIVISSIG0002_542,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,543,PSIVISSIG0002_543,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,544,PSIVISSIG0002_544,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,545,PSIVISSIG0002_545,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,15,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,546,PSIVISSIG0002_546,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,49,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,547,PSIVISSIG0002_547,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,868,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,548,PSIVISSIG0002_548,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,779,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,549,PSIVISSIG0002_549,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,962,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,550,PSIVISSIG0002_550,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,551,PSIVISSIG0002_551,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,544,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,552,PSIVISSIG0002_552,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,553,PSIVISSIG0002_553,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,554,PSIVISSIG0002_554,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,555,PSIVISSIG0002_555,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,857,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,556,PSIVISSIG0002_556,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,3,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,557,PSIVISSIG0002_557,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1310,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,558,PSIVISSIG0002_558,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,559,PSIVISSIG0002_559,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,560,PSIVISSIG0002_560,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,17,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,561,PSIVISSIG0002_561,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,922,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,562,PSIVISSIG0002_562,24,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,563,PSIVISSIG0002_563,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Censored at the last contact date,DEATH
PSIVISSIG0002,564,PSIVISSIG0002_564,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,29,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,565,PSIVISSIG0002_565,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,566,PSIVISSIG0002_566,26,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,343,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,567,PSIVISSIG0002_567,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,733,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,PSIVISSIG0002_568,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,569,PSIVISSIG0002_569,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,244,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,570,PSIVISSIG0002_570,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,201,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,571,PSIVISSIG0002_571,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,572,PSIVISSIG0002_572,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,4,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,573,PSIVISSIG0002_573,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,574,PSIVISSIG0002_574,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,89,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,575,PSIVISSIG0002_575,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,576,PSIVISSIG0002_576,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,53,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,577,PSIVISSIG0002_577,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,578,PSIVISSIG0002_578,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,994,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,579,PSIVISSIG0002_579,55,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,492,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,580,PSIVISSIG0002_580,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,581,PSIVISSIG0002_581,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,582,PSIVISSIG0002_582,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,583,PSIVISSIG0002_583,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,584,PSIVISSIG0002_584,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,585,PSIVISSIG0002_585,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1051,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,586,PSIVISSIG0002_586,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1617,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,587,PSIVISSIG0002_587,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,588,PSIVISSIG0002_588,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,589,PSIVISSIG0002_589,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,392,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,590,PSIVISSIG0002_590,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,591,PSIVISSIG0002_591,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,592,PSIVISSIG0002_592,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,859,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,593,PSIVISSIG0002_593,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,594,PSIVISSIG0002_594,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1667,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,PSIVISSIG0002_595,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,DEATH
PSIVISSIG0002,596,PSIVISSIG0002_596,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,597,PSIVISSIG0002_597,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,414,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,598,PSIVISSIG0002_598,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,316,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,599,PSIVISSIG0002_599,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,958,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,600,PSIVISSIG0002_600,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,601,PSIVISSIG0002_601,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,803,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,602,PSIVISSIG0002_602,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,46,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,603,PSIVISSIG0002_603,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,955,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,604,PSIVISSIG0002_604,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,54,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,605,PSIVISSIG0002_605,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,606,PSIVISSIG0002_606,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1226,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,607,PSIVISSIG0002_607,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,719,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,608,PSIVISSIG0002_608,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,222,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,609,PSIVISSIG0002_609,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,610,PSIVISSIG0002_610,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,611,PSIVISSIG0002_611,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,380,1,Censored at the last contact date,DEATH
PSIVISSIG0002,612,PSIVISSIG0002_612,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1286,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,613,PSIVISSIG0002_613,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,175,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,614,PSIVISSIG0002_614,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,615,PSIVISSIG0002_615,66,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1221,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,616,PSIVISSIG0002_616,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,854,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,PSIVISSIG0002_617,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,618,PSIVISSIG0002_618,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,619,PSIVISSIG0002_619,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,799,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,620,PSIVISSIG0002_620,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,164,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,621,PSIVISSIG0002_621,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,622,PSIVISSIG0002_622,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,983,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,623,PSIVISSIG0002_623,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,646,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,624,PSIVISSIG0002_624,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,625,PSIVISSIG0002_625,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1668,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,626,PSIVISSIG0002_626,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,627,PSIVISSIG0002_627,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,261,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,628,PSIVISSIG0002_628,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,570,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,629,PSIVISSIG0002_629,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,630,PSIVISSIG0002_630,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,907,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,631,PSIVISSIG0002_631,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,6,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,632,PSIVISSIG0002_632,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,633,PSIVISSIG0002_633,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1532,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,634,PSIVISSIG0002_634,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,635,PSIVISSIG0002_635,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,377,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,636,PSIVISSIG0002_636,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,315,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,637,PSIVISSIG0002_637,25,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,686,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,638,PSIVISSIG0002_638,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,366,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,639,PSIVISSIG0002_639,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,640,PSIVISSIG0002_640,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,641,PSIVISSIG0002_641,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,642,PSIVISSIG0002_642,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,578,1,Censored at the last contact date,DEATH
PSIVISSIG0002,643,PSIVISSIG0002_643,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,298,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,644,PSIVISSIG0002_644,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,37,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,645,PSIVISSIG0002_645,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,646,PSIVISSIG0002_646,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,558,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,647,PSIVISSIG0002_647,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,648,PSIVISSIG0002_648,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,649,PSIVISSIG0002_649,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,650,PSIVISSIG0002_650,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,651,PSIVISSIG0002_651,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,PSIVISSIG0002_652,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,825,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,653,PSIVISSIG0002_653,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,654,PSIVISSIG0002_654,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1588,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,655,PSIVISSIG0002_655,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,989,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,656,PSIVISSIG0002_656,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,657,PSIVISSIG0002_657,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,987,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,658,PSIVISSIG0002_658,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1109,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,659,PSIVISSIG0002_659,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,660,PSIVISSIG0002_660,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,661,PSIVISSIG0002_661,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,96,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,662,PSIVISSIG0002_662,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1023,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,663,PSIVISSIG0002_663,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,664,PSIVISSIG0002_664,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,705,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,665,PSIVISSIG0002_665,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,666,PSIVISSIG0002_666,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,667,PSIVISSIG0002_667,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,668,PSIVISSIG0002_668,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,669,PSIVISSIG0002_669,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1293,1,Censored at the last contact date,DEATH
PSIVISSIG0002,670,PSIVISSIG0002_670,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,802,1,Censored at the last contact date,DEATH
PSIVISSIG0002,671,PSIVISSIG0002_671,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,672,PSIVISSIG0002_672,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,673,PSIVISSIG0002_673,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1647,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,674,PSIVISSIG0002_674,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,675,PSIVISSIG0002_675,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,203,1,Censored at the last contact date,DEATH
PSIVISSIG0002,676,PSIVISSIG0002_676,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,92,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,677,PSIVISSIG0002_677,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,678,PSIVISSIG0002_678,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,679,PSIVISSIG0002_679,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,123,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,680,PSIVISSIG0002_680,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,681,PSIVISSIG0002_681,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,45,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,682,PSIVISSIG0002_682,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,683,PSIVISSIG0002_683,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,684,PSIVISSIG0002_684,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1011,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,685,PSIVISSIG0002_685,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,686,PSIVISSIG0002_686,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1124,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,PSIVISSIG0002_687,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,688,PSIVISSIG0002_688,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,689,PSIVISSIG0002_689,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,690,PSIVISSIG0002_690,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1305,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,691,PSIVISSIG0002_691,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1072,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,PSIVISSIG0002_692,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,693,PSIVISSIG0002_693,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,694,PSIVISSIG0002_694,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,695,PSIVISSIG0002_695,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1640,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,696,PSIVISSIG0002_696,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,Censored at the last contact date,DEATH
PSIVISSIG0002,697,PSIVISSIG0002_697,23,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,234,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,698,PSIVISSIG0002_698,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1426,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,699,PSIVISSIG0002_699,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,310,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,700,PSIVISSIG0002_700,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,206,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,701,PSIVISSIG0002_701,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,DEATH
PSIVISSIG0002,702,PSIVISSIG0002_702,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,221,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,703,PSIVISSIG0002_703,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,479,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,704,PSIVISSIG0002_704,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1651,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,705,PSIVISSIG0002_705,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1541,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,PSIVISSIG0002_706,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1529,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,707,PSIVISSIG0002_707,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,708,PSIVISSIG0002_708,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,94,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,709,PSIVISSIG0002_709,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1461,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,710,PSIVISSIG0002_710,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,711,PSIVISSIG0002_711,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1452,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,712,PSIVISSIG0002_712,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,745,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,713,PSIVISSIG0002_713,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,714,PSIVISSIG0002_714,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,715,PSIVISSIG0002_715,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,716,PSIVISSIG0002_716,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,717,PSIVISSIG0002_717,25,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1228,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,718,PSIVISSIG0002_718,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,877,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,719,PSIVISSIG0002_719,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,481,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,PSIVISSIG0002_720,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,721,PSIVISSIG0002_721,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,502,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,722,PSIVISSIG0002_722,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,842,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,723,PSIVISSIG0002_723,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,0,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,724,PSIVISSIG0002_724,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,824,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,725,PSIVISSIG0002_725,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,499,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,726,PSIVISSIG0002_726,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,727,PSIVISSIG0002_727,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,728,PSIVISSIG0002_728,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1683,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,729,PSIVISSIG0002_729,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,730,PSIVISSIG0002_730,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,731,PSIVISSIG0002_731,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,305,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,PSIVISSIG0002_732,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,733,PSIVISSIG0002_733,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,734,PSIVISSIG0002_734,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,735,PSIVISSIG0002_735,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1256,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,736,PSIVISSIG0002_736,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,737,PSIVISSIG0002_737,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,738,PSIVISSIG0002_738,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,730,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,739,PSIVISSIG0002_739,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,740,PSIVISSIG0002_740,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,741,PSIVISSIG0002_741,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,742,PSIVISSIG0002_742,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,533,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,743,PSIVISSIG0002_743,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,744,PSIVISSIG0002_744,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,745,PSIVISSIG0002_745,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,654,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,746,PSIVISSIG0002_746,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,671,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,747,PSIVISSIG0002_747,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,390,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,748,PSIVISSIG0002_748,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,429,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,749,PSIVISSIG0002_749,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,449,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,750,PSIVISSIG0002_750,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,DEATH
PSIVISSIG0002,751,PSIVISSIG0002_751,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,375,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,752,PSIVISSIG0002_752,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,753,PSIVISSIG0002_753,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,PSIVISSIG0002_754,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,PSIVISSIG0002_755,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,756,PSIVISSIG0002_756,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,757,PSIVISSIG0002_757,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,758,PSIVISSIG0002_758,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1000,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,759,PSIVISSIG0002_759,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,931,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,760,PSIVISSIG0002_760,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,247,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,761,PSIVISSIG0002_761,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,240,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,762,PSIVISSIG0002_762,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,763,PSIVISSIG0002_763,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,764,PSIVISSIG0002_764,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,765,PSIVISSIG0002_765,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,751,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,766,PSIVISSIG0002_766,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,767,PSIVISSIG0002_767,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,768,PSIVISSIG0002_768,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,905,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,769,PSIVISSIG0002_769,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,809,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,770,PSIVISSIG0002_770,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,423,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,771,PSIVISSIG0002_771,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,772,PSIVISSIG0002_772,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,7,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,773,PSIVISSIG0002_773,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,774,PSIVISSIG0002_774,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,433,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,775,PSIVISSIG0002_775,23,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,776,PSIVISSIG0002_776,31,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,777,PSIVISSIG0002_777,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,778,PSIVISSIG0002_778,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,779,PSIVISSIG0002_779,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1438,1,Censored at the last contact date,DEATH
PSIVISSIG0002,780,PSIVISSIG0002_780,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,781,PSIVISSIG0002_781,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,203,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,782,PSIVISSIG0002_782,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,783,PSIVISSIG0002_783,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,754,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,784,PSIVISSIG0002_784,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,932,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,785,PSIVISSIG0002_785,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,946,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,786,PSIVISSIG0002_786,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1008,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,787,PSIVISSIG0002_787,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,788,PSIVISSIG0002_788,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,789,PSIVISSIG0002_789,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,790,PSIVISSIG0002_790,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,791,PSIVISSIG0002_791,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,224,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,792,PSIVISSIG0002_792,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,793,PSIVISSIG0002_793,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,794,PSIVISSIG0002_794,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,795,PSIVISSIG0002_795,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1542,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,796,PSIVISSIG0002_796,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,797,PSIVISSIG0002_797,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1696,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,798,PSIVISSIG0002_798,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,799,PSIVISSIG0002_799,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,800,PSIVISSIG0002_800,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,92,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,801,PSIVISSIG0002_801,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,2,1,Censored at the last contact date,DEATH
PSIVISSIG0002,802,PSIVISSIG0002_802,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,803,PSIVISSIG0002_803,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,982,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,804,PSIVISSIG0002_804,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,805,PSIVISSIG0002_805,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,806,PSIVISSIG0002_806,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1134,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,807,PSIVISSIG0002_807,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,808,PSIVISSIG0002_808,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,809,PSIVISSIG0002_809,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,837,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,810,PSIVISSIG0002_810,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1474,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,811,PSIVISSIG0002_811,59,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,812,PSIVISSIG0002_812,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,813,PSIVISSIG0002_813,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,757,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,814,PSIVISSIG0002_814,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,815,PSIVISSIG0002_815,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1596,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,816,PSIVISSIG0002_816,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,38,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,817,PSIVISSIG0002_817,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,749,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,818,PSIVISSIG0002_818,27,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,876,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,819,PSIVISSIG0002_819,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,820,PSIVISSIG0002_820,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,102,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,821,PSIVISSIG0002_821,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,822,PSIVISSIG0002_822,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,823,PSIVISSIG0002_823,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,PSIVISSIG0002_824,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,661,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,825,PSIVISSIG0002_825,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,826,PSIVISSIG0002_826,30,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,685,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,827,PSIVISSIG0002_827,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,828,PSIVISSIG0002_828,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1205,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,829,PSIVISSIG0002_829,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,373,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,830,PSIVISSIG0002_830,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,302,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,831,PSIVISSIG0002_831,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,832,PSIVISSIG0002_832,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1629,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,833,PSIVISSIG0002_833,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,834,PSIVISSIG0002_834,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,835,PSIVISSIG0002_835,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,836,PSIVISSIG0002_836,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,837,PSIVISSIG0002_837,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,180,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,838,PSIVISSIG0002_838,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,682,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,839,PSIVISSIG0002_839,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,840,PSIVISSIG0002_840,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,841,PSIVISSIG0002_841,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,842,PSIVISSIG0002_842,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,358,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,843,PSIVISSIG0002_843,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,844,PSIVISSIG0002_844,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,845,PSIVISSIG0002_845,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1368,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,846,PSIVISSIG0002_846,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,27,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,847,PSIVISSIG0002_847,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,848,PSIVISSIG0002_848,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,611,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,849,PSIVISSIG0002_849,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,732,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,850,PSIVISSIG0002_850,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,851,PSIVISSIG0002_851,25,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,586,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,852,PSIVISSIG0002_852,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1418,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,853,PSIVISSIG0002_853,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,PSIVISSIG0002_854,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,575,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,855,PSIVISSIG0002_855,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,856,PSIVISSIG0002_856,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1208,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,857,PSIVISSIG0002_857,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,271,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,858,PSIVISSIG0002_858,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,993,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,859,PSIVISSIG0002_859,68,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1617,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,PSIVISSIG0002_860,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,861,PSIVISSIG0002_861,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,862,PSIVISSIG0002_862,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,962,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,863,PSIVISSIG0002_863,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,551,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,864,PSIVISSIG0002_864,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,865,PSIVISSIG0002_865,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,866,PSIVISSIG0002_866,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,29,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,PSIVISSIG0002_867,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,662,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,868,PSIVISSIG0002_868,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,705,1,Censored at the last contact date,DEATH
PSIVISSIG0002,869,PSIVISSIG0002_869,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,110,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,870,PSIVISSIG0002_870,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,871,PSIVISSIG0002_871,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1353,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,872,PSIVISSIG0002_872,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1085,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,873,PSIVISSIG0002_873,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1264,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,874,PSIVISSIG0002_874,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,154,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,875,PSIVISSIG0002_875,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,876,PSIVISSIG0002_876,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1770,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,877,PSIVISSIG0002_877,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,293,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,878,PSIVISSIG0002_878,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,913,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,879,PSIVISSIG0002_879,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,880,PSIVISSIG0002_880,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1012,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,881,PSIVISSIG0002_881,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,528,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,882,PSIVISSIG0002_882,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,165,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,883,PSIVISSIG0002_883,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,884,PSIVISSIG0002_884,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,885,PSIVISSIG0002_885,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,886,PSIVISSIG0002_886,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,887,PSIVISSIG0002_887,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,888,PSIVISSIG0002_888,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,280,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,889,PSIVISSIG0002_889,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1316,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,890,PSIVISSIG0002_890,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1427,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,891,PSIVISSIG0002_891,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,892,PSIVISSIG0002_892,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,320,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,893,PSIVISSIG0002_893,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,788,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,894,PSIVISSIG0002_894,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,372,1,Censored at the last contact date,DEATH
PSIVISSIG0002,895,PSIVISSIG0002_895,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,896,PSIVISSIG0002_896,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1561,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,897,PSIVISSIG0002_897,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,110,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,898,PSIVISSIG0002_898,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,899,PSIVISSIG0002_899,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,900,PSIVISSIG0002_900,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,14,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,901,PSIVISSIG0002_901,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,218,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,902,PSIVISSIG0002_902,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,903,PSIVISSIG0002_903,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,904,PSIVISSIG0002_904,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,905,PSIVISSIG0002_905,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,906,PSIVISSIG0002_906,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1075,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,907,PSIVISSIG0002_907,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,957,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,908,PSIVISSIG0002_908,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,90,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,909,PSIVISSIG0002_909,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,910,PSIVISSIG0002_910,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,918,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,911,PSIVISSIG0002_911,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,38,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,912,PSIVISSIG0002_912,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,913,PSIVISSIG0002_913,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,91,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,914,PSIVISSIG0002_914,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,PSIVISSIG0002_915,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,916,PSIVISSIG0002_916,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,558,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,917,PSIVISSIG0002_917,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,662,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,918,PSIVISSIG0002_918,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1315,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,919,PSIVISSIG0002_919,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,23,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,920,PSIVISSIG0002_920,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,102,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,921,PSIVISSIG0002_921,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,922,PSIVISSIG0002_922,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,964,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,923,PSIVISSIG0002_923,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1331,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,924,PSIVISSIG0002_924,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,925,PSIVISSIG0002_925,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,841,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,926,PSIVISSIG0002_926,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,22,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,927,PSIVISSIG0002_927,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,928,PSIVISSIG0002_928,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,929,PSIVISSIG0002_929,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,930,PSIVISSIG0002_930,36,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,20,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,931,PSIVISSIG0002_931,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,932,PSIVISSIG0002_932,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1703,1,Censored at the last contact date,DEATH
PSIVISSIG0002,933,PSIVISSIG0002_933,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1185,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,934,PSIVISSIG0002_934,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1287,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,935,PSIVISSIG0002_935,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,936,PSIVISSIG0002_936,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1513,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,937,PSIVISSIG0002_937,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1712,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,938,PSIVISSIG0002_938,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,939,PSIVISSIG0002_939,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,306,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,940,PSIVISSIG0002_940,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,95,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,941,PSIVISSIG0002_941,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,942,PSIVISSIG0002_942,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1514,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,943,PSIVISSIG0002_943,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,944,PSIVISSIG0002_944,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,377,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,945,PSIVISSIG0002_945,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1015,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,946,PSIVISSIG0002_946,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,355,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,947,PSIVISSIG0002_947,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,948,PSIVISSIG0002_948,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,219,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,949,PSIVISSIG0002_949,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,950,PSIVISSIG0002_950,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,722,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,951,PSIVISSIG0002_951,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,952,PSIVISSIG0002_952,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,953,PSIVISSIG0002_953,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,671,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,PSIVISSIG0002_954,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1270,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,955,PSIVISSIG0002_955,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,956,PSIVISSIG0002_956,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,359,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,957,PSIVISSIG0002_957,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,347,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,958,PSIVISSIG0002_958,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,71,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,959,PSIVISSIG0002_959,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1482,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,960,PSIVISSIG0002_960,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,928,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,961,PSIVISSIG0002_961,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,266,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,962,PSIVISSIG0002_962,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,640,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,963,PSIVISSIG0002_963,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,938,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,964,PSIVISSIG0002_964,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,965,PSIVISSIG0002_965,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,966,PSIVISSIG0002_966,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,967,PSIVISSIG0002_967,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,613,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,968,PSIVISSIG0002_968,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,404,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,969,PSIVISSIG0002_969,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,970,PSIVISSIG0002_970,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,971,PSIVISSIG0002_971,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,972,PSIVISSIG0002_972,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,973,PSIVISSIG0002_973,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,944,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,974,PSIVISSIG0002_974,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,975,PSIVISSIG0002_975,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,976,PSIVISSIG0002_976,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,853,1,Censored at the last contact date,DEATH
PSIVISSIG0002,977,PSIVISSIG0002_977,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,456,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,PSIVISSIG0002_978,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1373,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,979,PSIVISSIG0002_979,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,980,PSIVISSIG0002_980,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,693,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,981,PSIVISSIG0002_981,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1032,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,982,PSIVISSIG0002_982,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,343,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,983,PSIVISSIG0002_983,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,984,PSIVISSIG0002_984,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,985,PSIVISSIG0002_985,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,986,PSIVISSIG0002_986,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,716,1,Censored at the last contact date,DEATH
PSIVISSIG0002,987,PSIVISSIG0002_987,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,988,PSIVISSIG0002_988,68,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,133,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,989,PSIVISSIG0002_989,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,737,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,990,PSIVISSIG0002_990,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,991,PSIVISSIG0002_991,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,70,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,992,PSIVISSIG0002_992,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,867,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,993,PSIVISSIG0002_993,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,368,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,994,PSIVISSIG0002_994,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1378,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,995,PSIVISSIG0002_995,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,996,PSIVISSIG0002_996,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,352,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,997,PSIVISSIG0002_997,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1374,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,998,PSIVISSIG0002_998,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,999,PSIVISSIG0002_999,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,329,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1000,PSIVISSIG0002_1000,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,PSIVISSIG0002_1001,26,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1183,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1002,PSIVISSIG0002_1002,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,170,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,PSIVISSIG0002_1003,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,38,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1004,PSIVISSIG0002_1004,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1005,PSIVISSIG0002_1005,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,517,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1006,PSIVISSIG0002_1006,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,9,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1007,PSIVISSIG0002_1007,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1008,PSIVISSIG0002_1008,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,66,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1009,PSIVISSIG0002_1009,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1010,PSIVISSIG0002_1010,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,77,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1011,PSIVISSIG0002_1011,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1012,PSIVISSIG0002_1012,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,918,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1013,PSIVISSIG0002_1013,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,236,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1014,PSIVISSIG0002_1014,54,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1745,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1015,PSIVISSIG0002_1015,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1126,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1016,PSIVISSIG0002_1016,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,410,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1017,PSIVISSIG0002_1017,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1018,PSIVISSIG0002_1018,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1019,PSIVISSIG0002_1019,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1331,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1020,PSIVISSIG0002_1020,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1005,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1021,PSIVISSIG0002_1021,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,561,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1022,PSIVISSIG0002_1022,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1718,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1023,PSIVISSIG0002_1023,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1024,PSIVISSIG0002_1024,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1635,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1025,PSIVISSIG0002_1025,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,357,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1026,PSIVISSIG0002_1026,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,880,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1027,PSIVISSIG0002_1027,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,628,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1028,PSIVISSIG0002_1028,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1029,PSIVISSIG0002_1029,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1030,PSIVISSIG0002_1030,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1031,PSIVISSIG0002_1031,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,417,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1032,PSIVISSIG0002_1032,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,31,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1033,PSIVISSIG0002_1033,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1034,PSIVISSIG0002_1034,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,263,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1035,PSIVISSIG0002_1035,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1036,PSIVISSIG0002_1036,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,958,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1037,PSIVISSIG0002_1037,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1038,PSIVISSIG0002_1038,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,384,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1039,PSIVISSIG0002_1039,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,505,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1040,PSIVISSIG0002_1040,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1041,PSIVISSIG0002_1041,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1042,PSIVISSIG0002_1042,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,70,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1043,PSIVISSIG0002_1043,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1044,PSIVISSIG0002_1044,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1045,PSIVISSIG0002_1045,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1046,PSIVISSIG0002_1046,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,866,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1047,PSIVISSIG0002_1047,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1048,PSIVISSIG0002_1048,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1238,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1049,PSIVISSIG0002_1049,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1050,PSIVISSIG0002_1050,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1051,PSIVISSIG0002_1051,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1052,PSIVISSIG0002_1052,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,556,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1053,PSIVISSIG0002_1053,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1054,PSIVISSIG0002_1054,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,206,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1055,PSIVISSIG0002_1055,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1056,PSIVISSIG0002_1056,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1057,PSIVISSIG0002_1057,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1058,PSIVISSIG0002_1058,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,9,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1059,PSIVISSIG0002_1059,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1060,PSIVISSIG0002_1060,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1263,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1061,PSIVISSIG0002_1061,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,242,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1062,PSIVISSIG0002_1062,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,721,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1063,PSIVISSIG0002_1063,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1064,PSIVISSIG0002_1064,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1065,PSIVISSIG0002_1065,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,792,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1066,PSIVISSIG0002_1066,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1067,PSIVISSIG0002_1067,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1014,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1068,PSIVISSIG0002_1068,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,385,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1069,PSIVISSIG0002_1069,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1057,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1070,PSIVISSIG0002_1070,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1071,PSIVISSIG0002_1071,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1741,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1072,PSIVISSIG0002_1072,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,265,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1073,PSIVISSIG0002_1073,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1074,PSIVISSIG0002_1074,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1075,PSIVISSIG0002_1075,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,123,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1076,PSIVISSIG0002_1076,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1077,PSIVISSIG0002_1077,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1078,PSIVISSIG0002_1078,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1564,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1079,PSIVISSIG0002_1079,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1080,PSIVISSIG0002_1080,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1081,PSIVISSIG0002_1081,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1082,PSIVISSIG0002_1082,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,198,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1083,PSIVISSIG0002_1083,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1550,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1084,PSIVISSIG0002_1084,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1751,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1085,PSIVISSIG0002_1085,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1086,PSIVISSIG0002_1086,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,551,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1087,PSIVISSIG0002_1087,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1088,PSIVISSIG0002_1088,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1089,PSIVISSIG0002_1089,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1112,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1090,PSIVISSIG0002_1090,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1091,PSIVISSIG0002_1091,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1092,PSIVISSIG0002_1092,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1505,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1093,PSIVISSIG0002_1093,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,46,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1094,PSIVISSIG0002_1094,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1457,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1095,PSIVISSIG0002_1095,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,371,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1096,PSIVISSIG0002_1096,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1097,PSIVISSIG0002_1097,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1098,PSIVISSIG0002_1098,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,431,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1099,PSIVISSIG0002_1099,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,486,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1100,PSIVISSIG0002_1100,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1101,PSIVISSIG0002_1101,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,493,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1102,PSIVISSIG0002_1102,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1593,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1103,PSIVISSIG0002_1103,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1104,PSIVISSIG0002_1104,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1105,PSIVISSIG0002_1105,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,812,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1106,PSIVISSIG0002_1106,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1107,PSIVISSIG0002_1107,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,328,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1108,PSIVISSIG0002_1108,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1109,PSIVISSIG0002_1109,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,116,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1110,PSIVISSIG0002_1110,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,82,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1111,PSIVISSIG0002_1111,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1087,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1112,PSIVISSIG0002_1112,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,699,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1113,PSIVISSIG0002_1113,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,193,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1114,PSIVISSIG0002_1114,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,27,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1115,PSIVISSIG0002_1115,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,563,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1116,PSIVISSIG0002_1116,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1117,PSIVISSIG0002_1117,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,39,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1118,PSIVISSIG0002_1118,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,334,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1119,PSIVISSIG0002_1119,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1120,PSIVISSIG0002_1120,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,13,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1121,PSIVISSIG0002_1121,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1122,PSIVISSIG0002_1122,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,84,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1123,PSIVISSIG0002_1123,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1124,PSIVISSIG0002_1124,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,45,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1125,PSIVISSIG0002_1125,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1126,PSIVISSIG0002_1126,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1127,PSIVISSIG0002_1127,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,85,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1128,PSIVISSIG0002_1128,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,927,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1129,PSIVISSIG0002_1129,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1130,PSIVISSIG0002_1130,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1223,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1131,PSIVISSIG0002_1131,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1210,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1132,PSIVISSIG0002_1132,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1133,PSIVISSIG0002_1133,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1134,PSIVISSIG0002_1134,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1445,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1135,PSIVISSIG0002_1135,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1136,PSIVISSIG0002_1136,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1016,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1137,PSIVISSIG0002_1137,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1138,PSIVISSIG0002_1138,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,308,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1139,PSIVISSIG0002_1139,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1140,PSIVISSIG0002_1140,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1141,PSIVISSIG0002_1141,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,773,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1142,PSIVISSIG0002_1142,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1566,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1143,PSIVISSIG0002_1143,66,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,457,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1144,PSIVISSIG0002_1144,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1145,PSIVISSIG0002_1145,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1729,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1146,PSIVISSIG0002_1146,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1147,PSIVISSIG0002_1147,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1314,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1148,PSIVISSIG0002_1148,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1149,PSIVISSIG0002_1149,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,575,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1150,PSIVISSIG0002_1150,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,72,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1151,PSIVISSIG0002_1151,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1054,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1152,PSIVISSIG0002_1152,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,45,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1153,PSIVISSIG0002_1153,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1282,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1154,PSIVISSIG0002_1154,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,300,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1155,PSIVISSIG0002_1155,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,574,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1156,PSIVISSIG0002_1156,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,282,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1157,PSIVISSIG0002_1157,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1158,PSIVISSIG0002_1158,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1159,PSIVISSIG0002_1159,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1160,PSIVISSIG0002_1160,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,246,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1161,PSIVISSIG0002_1161,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1069,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1162,PSIVISSIG0002_1162,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,80,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1163,PSIVISSIG0002_1163,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,69,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1164,PSIVISSIG0002_1164,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1165,PSIVISSIG0002_1165,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,858,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1166,PSIVISSIG0002_1166,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,592,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1167,PSIVISSIG0002_1167,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1168,PSIVISSIG0002_1168,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1169,PSIVISSIG0002_1169,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1170,PSIVISSIG0002_1170,55,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1171,PSIVISSIG0002_1171,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,612,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1172,PSIVISSIG0002_1172,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1173,PSIVISSIG0002_1173,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1174,PSIVISSIG0002_1174,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,149,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1175,PSIVISSIG0002_1175,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1000,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1176,PSIVISSIG0002_1176,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1177,PSIVISSIG0002_1177,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,914,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1178,PSIVISSIG0002_1178,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,999,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1179,PSIVISSIG0002_1179,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1013,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1180,PSIVISSIG0002_1180,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1181,PSIVISSIG0002_1181,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,660,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1182,PSIVISSIG0002_1182,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1132,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1183,PSIVISSIG0002_1183,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,917,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1184,PSIVISSIG0002_1184,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1185,PSIVISSIG0002_1185,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1186,PSIVISSIG0002_1186,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1187,PSIVISSIG0002_1187,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1188,PSIVISSIG0002_1188,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1189,PSIVISSIG0002_1189,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,309,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1190,PSIVISSIG0002_1190,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1191,PSIVISSIG0002_1191,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1192,PSIVISSIG0002_1192,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,261,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1193,PSIVISSIG0002_1193,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,79,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1194,PSIVISSIG0002_1194,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1195,PSIVISSIG0002_1195,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1196,PSIVISSIG0002_1196,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1197,PSIVISSIG0002_1197,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1708,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1198,PSIVISSIG0002_1198,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1199,PSIVISSIG0002_1199,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1271,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1200,PSIVISSIG0002_1200,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1201,PSIVISSIG0002_1201,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1202,PSIVISSIG0002_1202,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1203,PSIVISSIG0002_1203,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1410,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1204,PSIVISSIG0002_1204,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,512,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1205,PSIVISSIG0002_1205,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1206,PSIVISSIG0002_1206,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1622,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1207,PSIVISSIG0002_1207,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,493,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1208,PSIVISSIG0002_1208,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,892,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1209,PSIVISSIG0002_1209,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1210,PSIVISSIG0002_1210,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1211,PSIVISSIG0002_1211,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,693,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1212,PSIVISSIG0002_1212,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1213,PSIVISSIG0002_1213,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1214,PSIVISSIG0002_1214,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1215,PSIVISSIG0002_1215,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,43,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1216,PSIVISSIG0002_1216,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1581,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1217,PSIVISSIG0002_1217,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1378,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1218,PSIVISSIG0002_1218,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,188,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1219,PSIVISSIG0002_1219,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1002,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1220,PSIVISSIG0002_1220,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,445,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1221,PSIVISSIG0002_1221,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,107,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1222,PSIVISSIG0002_1222,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,360,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1223,PSIVISSIG0002_1223,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1224,PSIVISSIG0002_1224,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,835,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1225,PSIVISSIG0002_1225,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1226,PSIVISSIG0002_1226,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1227,PSIVISSIG0002_1227,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1228,PSIVISSIG0002_1228,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1229,PSIVISSIG0002_1229,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1230,PSIVISSIG0002_1230,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1231,PSIVISSIG0002_1231,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1232,PSIVISSIG0002_1232,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1233,PSIVISSIG0002_1233,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1739,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1234,PSIVISSIG0002_1234,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,554,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1235,PSIVISSIG0002_1235,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1236,PSIVISSIG0002_1236,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1237,PSIVISSIG0002_1237,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,648,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1238,PSIVISSIG0002_1238,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1239,PSIVISSIG0002_1239,27,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1240,PSIVISSIG0002_1240,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,2,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1241,PSIVISSIG0002_1241,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1663,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1242,PSIVISSIG0002_1242,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1351,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1243,PSIVISSIG0002_1243,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1244,PSIVISSIG0002_1244,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,517,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1245,PSIVISSIG0002_1245,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1246,PSIVISSIG0002_1246,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,260,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1247,PSIVISSIG0002_1247,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1248,PSIVISSIG0002_1248,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1249,PSIVISSIG0002_1249,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1182,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1250,PSIVISSIG0002_1250,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1251,PSIVISSIG0002_1251,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,321,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1252,PSIVISSIG0002_1252,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1253,PSIVISSIG0002_1253,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,559,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1254,PSIVISSIG0002_1254,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1255,PSIVISSIG0002_1255,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1256,PSIVISSIG0002_1256,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1257,PSIVISSIG0002_1257,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,180,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1258,PSIVISSIG0002_1258,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1259,PSIVISSIG0002_1259,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1110,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1260,PSIVISSIG0002_1260,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,269,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1261,PSIVISSIG0002_1261,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1262,PSIVISSIG0002_1262,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1309,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1263,PSIVISSIG0002_1263,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,135,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1264,PSIVISSIG0002_1264,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,497,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1265,PSIVISSIG0002_1265,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,530,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1266,PSIVISSIG0002_1266,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1267,PSIVISSIG0002_1267,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1268,PSIVISSIG0002_1268,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,707,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1269,PSIVISSIG0002_1269,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1759,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1270,PSIVISSIG0002_1270,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,306,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1271,PSIVISSIG0002_1271,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1272,PSIVISSIG0002_1272,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,591,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1273,PSIVISSIG0002_1273,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1482,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1274,PSIVISSIG0002_1274,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1768,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1275,PSIVISSIG0002_1275,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1276,PSIVISSIG0002_1276,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1663,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1277,PSIVISSIG0002_1277,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1077,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1278,PSIVISSIG0002_1278,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1079,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1279,PSIVISSIG0002_1279,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1065,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1280,PSIVISSIG0002_1280,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,148,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1281,PSIVISSIG0002_1281,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,562,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1282,PSIVISSIG0002_1282,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,58,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1283,PSIVISSIG0002_1283,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1284,PSIVISSIG0002_1284,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1285,PSIVISSIG0002_1285,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,139,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1286,PSIVISSIG0002_1286,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1287,PSIVISSIG0002_1287,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1288,PSIVISSIG0002_1288,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,484,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1289,PSIVISSIG0002_1289,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1290,PSIVISSIG0002_1290,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1291,PSIVISSIG0002_1291,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,993,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1292,PSIVISSIG0002_1292,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1293,PSIVISSIG0002_1293,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1294,PSIVISSIG0002_1294,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1295,PSIVISSIG0002_1295,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1296,PSIVISSIG0002_1296,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,8,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1297,PSIVISSIG0002_1297,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1298,PSIVISSIG0002_1298,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1299,PSIVISSIG0002_1299,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1300,PSIVISSIG0002_1300,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,701,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1301,PSIVISSIG0002_1301,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1302,PSIVISSIG0002_1302,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1303,PSIVISSIG0002_1303,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1084,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1304,PSIVISSIG0002_1304,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,327,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1305,PSIVISSIG0002_1305,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,196,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1306,PSIVISSIG0002_1306,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,448,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1307,PSIVISSIG0002_1307,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,543,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1308,PSIVISSIG0002_1308,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1309,PSIVISSIG0002_1309,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1310,PSIVISSIG0002_1310,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1228,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1311,PSIVISSIG0002_1311,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,48,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1312,PSIVISSIG0002_1312,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,825,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1313,PSIVISSIG0002_1313,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1314,PSIVISSIG0002_1314,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,200,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1315,PSIVISSIG0002_1315,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,241,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1316,PSIVISSIG0002_1316,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,966,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1317,PSIVISSIG0002_1317,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,314,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1318,PSIVISSIG0002_1318,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1319,PSIVISSIG0002_1319,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1511,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1320,PSIVISSIG0002_1320,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1668,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1321,PSIVISSIG0002_1321,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1322,PSIVISSIG0002_1322,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,685,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1323,PSIVISSIG0002_1323,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1324,PSIVISSIG0002_1324,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,107,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1325,PSIVISSIG0002_1325,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,448,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1326,PSIVISSIG0002_1326,64,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1327,PSIVISSIG0002_1327,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1328,PSIVISSIG0002_1328,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1697,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1329,PSIVISSIG0002_1329,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1330,PSIVISSIG0002_1330,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1474,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1331,PSIVISSIG0002_1331,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,116,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1332,PSIVISSIG0002_1332,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1319,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1333,PSIVISSIG0002_1333,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1334,PSIVISSIG0002_1334,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1335,PSIVISSIG0002_1335,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,313,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1336,PSIVISSIG0002_1336,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,968,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1337,PSIVISSIG0002_1337,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1338,PSIVISSIG0002_1338,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1558,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1339,PSIVISSIG0002_1339,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,181,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1340,PSIVISSIG0002_1340,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,830,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1341,PSIVISSIG0002_1341,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1035,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1342,PSIVISSIG0002_1342,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1343,PSIVISSIG0002_1343,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,806,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1344,PSIVISSIG0002_1344,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1518,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1345,PSIVISSIG0002_1345,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,101,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1346,PSIVISSIG0002_1346,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1347,PSIVISSIG0002_1347,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,426,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1348,PSIVISSIG0002_1348,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1349,PSIVISSIG0002_1349,29,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,195,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1350,PSIVISSIG0002_1350,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1682,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1351,PSIVISSIG0002_1351,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,346,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1352,PSIVISSIG0002_1352,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1762,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1353,PSIVISSIG0002_1353,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,842,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1354,PSIVISSIG0002_1354,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,329,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1355,PSIVISSIG0002_1355,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1356,PSIVISSIG0002_1356,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,898,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1357,PSIVISSIG0002_1357,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1358,PSIVISSIG0002_1358,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1359,PSIVISSIG0002_1359,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1360,PSIVISSIG0002_1360,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1361,PSIVISSIG0002_1361,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,954,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1362,PSIVISSIG0002_1362,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,579,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1363,PSIVISSIG0002_1363,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1666,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1364,PSIVISSIG0002_1364,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,890,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1365,PSIVISSIG0002_1365,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1366,PSIVISSIG0002_1366,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1367,PSIVISSIG0002_1367,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,747,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1368,PSIVISSIG0002_1368,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,994,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1369,PSIVISSIG0002_1369,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,260,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1370,PSIVISSIG0002_1370,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1371,PSIVISSIG0002_1371,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1372,PSIVISSIG0002_1372,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,13,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1373,PSIVISSIG0002_1373,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1374,PSIVISSIG0002_1374,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,858,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1375,PSIVISSIG0002_1375,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1376,PSIVISSIG0002_1376,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,670,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1377,PSIVISSIG0002_1377,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,31,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1378,PSIVISSIG0002_1378,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,283,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1379,PSIVISSIG0002_1379,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1001,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1380,PSIVISSIG0002_1380,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1381,PSIVISSIG0002_1381,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1382,PSIVISSIG0002_1382,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1115,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1383,PSIVISSIG0002_1383,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1017,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1384,PSIVISSIG0002_1384,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,293,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1385,PSIVISSIG0002_1385,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1386,PSIVISSIG0002_1386,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,945,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1387,PSIVISSIG0002_1387,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1388,PSIVISSIG0002_1388,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,2,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1389,PSIVISSIG0002_1389,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,675,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1390,PSIVISSIG0002_1390,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,271,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1391,PSIVISSIG0002_1391,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,161,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1392,PSIVISSIG0002_1392,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1393,PSIVISSIG0002_1393,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1003,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1394,PSIVISSIG0002_1394,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1415,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1395,PSIVISSIG0002_1395,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,177,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1396,PSIVISSIG0002_1396,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,119,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1397,PSIVISSIG0002_1397,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1398,PSIVISSIG0002_1398,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,905,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1399,PSIVISSIG0002_1399,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1350,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1400,PSIVISSIG0002_1400,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1636,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1401,PSIVISSIG0002_1401,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1402,PSIVISSIG0002_1402,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,74,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1403,PSIVISSIG0002_1403,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,899,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1404,PSIVISSIG0002_1404,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,382,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1405,PSIVISSIG0002_1405,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1406,PSIVISSIG0002_1406,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1407,PSIVISSIG0002_1407,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1408,PSIVISSIG0002_1408,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,539,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1409,PSIVISSIG0002_1409,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1410,PSIVISSIG0002_1410,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,158,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1411,PSIVISSIG0002_1411,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1412,PSIVISSIG0002_1412,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,830,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1413,PSIVISSIG0002_1413,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,83,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1414,PSIVISSIG0002_1414,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1415,PSIVISSIG0002_1415,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1416,PSIVISSIG0002_1416,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1257,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1417,PSIVISSIG0002_1417,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1418,PSIVISSIG0002_1418,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,533,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1419,PSIVISSIG0002_1419,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1420,PSIVISSIG0002_1420,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1214,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1421,PSIVISSIG0002_1421,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1422,PSIVISSIG0002_1422,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,254,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1423,PSIVISSIG0002_1423,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,490,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1424,PSIVISSIG0002_1424,69,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,184,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1425,PSIVISSIG0002_1425,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1426,PSIVISSIG0002_1426,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,760,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1427,PSIVISSIG0002_1427,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1428,PSIVISSIG0002_1428,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,773,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1429,PSIVISSIG0002_1429,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1430,PSIVISSIG0002_1430,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1431,PSIVISSIG0002_1431,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1065,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1432,PSIVISSIG0002_1432,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1433,PSIVISSIG0002_1433,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1434,PSIVISSIG0002_1434,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1435,PSIVISSIG0002_1435,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,142,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1436,PSIVISSIG0002_1436,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1728,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1437,PSIVISSIG0002_1437,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1438,PSIVISSIG0002_1438,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,115,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1439,PSIVISSIG0002_1439,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,163,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1440,PSIVISSIG0002_1440,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1294,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1441,PSIVISSIG0002_1441,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1442,PSIVISSIG0002_1442,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,96,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1443,PSIVISSIG0002_1443,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1444,PSIVISSIG0002_1444,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1445,PSIVISSIG0002_1445,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1446,PSIVISSIG0002_1446,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1447,PSIVISSIG0002_1447,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,152,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1448,PSIVISSIG0002_1448,77,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,90,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1449,PSIVISSIG0002_1449,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1450,PSIVISSIG0002_1450,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1451,PSIVISSIG0002_1451,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,281,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1452,PSIVISSIG0002_1452,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1453,PSIVISSIG0002_1453,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,64,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1454,PSIVISSIG0002_1454,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,14,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1455,PSIVISSIG0002_1455,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,927,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1456,PSIVISSIG0002_1456,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1457,PSIVISSIG0002_1457,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,351,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1458,PSIVISSIG0002_1458,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,437,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1459,PSIVISSIG0002_1459,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,498,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1460,PSIVISSIG0002_1460,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1461,PSIVISSIG0002_1461,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,749,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1462,PSIVISSIG0002_1462,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,331,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1463,PSIVISSIG0002_1463,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,421,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1464,PSIVISSIG0002_1464,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1465,PSIVISSIG0002_1465,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,960,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1466,PSIVISSIG0002_1466,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1467,PSIVISSIG0002_1467,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1468,PSIVISSIG0002_1468,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1469,PSIVISSIG0002_1469,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,831,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1470,PSIVISSIG0002_1470,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1471,PSIVISSIG0002_1471,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,606,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1472,PSIVISSIG0002_1472,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,982,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1473,PSIVISSIG0002_1473,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,859,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1474,PSIVISSIG0002_1474,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1475,PSIVISSIG0002_1475,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,807,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1476,PSIVISSIG0002_1476,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1043,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1477,PSIVISSIG0002_1477,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1371,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1478,PSIVISSIG0002_1478,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,372,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1479,PSIVISSIG0002_1479,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,52,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1480,PSIVISSIG0002_1480,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1481,PSIVISSIG0002_1481,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1482,PSIVISSIG0002_1482,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1483,PSIVISSIG0002_1483,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,741,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1484,PSIVISSIG0002_1484,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,47,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1485,PSIVISSIG0002_1485,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,127,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1486,PSIVISSIG0002_1486,48,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1487,PSIVISSIG0002_1487,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,919,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1488,PSIVISSIG0002_1488,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,633,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1489,PSIVISSIG0002_1489,23,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1490,PSIVISSIG0002_1490,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1491,PSIVISSIG0002_1491,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,801,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1492,PSIVISSIG0002_1492,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,847,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1493,PSIVISSIG0002_1493,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1494,PSIVISSIG0002_1494,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1495,PSIVISSIG0002_1495,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1496,PSIVISSIG0002_1496,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1497,PSIVISSIG0002_1497,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1498,PSIVISSIG0002_1498,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1499,PSIVISSIG0002_1499,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1500,PSIVISSIG0002_1500,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,786,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1501,PSIVISSIG0002_1501,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1502,PSIVISSIG0002_1502,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1051,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1503,PSIVISSIG0002_1503,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,397,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1504,PSIVISSIG0002_1504,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1505,PSIVISSIG0002_1505,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,427,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1506,PSIVISSIG0002_1506,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1507,PSIVISSIG0002_1507,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1448,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1508,PSIVISSIG0002_1508,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1509,PSIVISSIG0002_1509,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1510,PSIVISSIG0002_1510,61,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1511,PSIVISSIG0002_1511,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1626,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1512,PSIVISSIG0002_1512,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,964,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1513,PSIVISSIG0002_1513,23,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1514,PSIVISSIG0002_1514,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,91,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1515,PSIVISSIG0002_1515,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1441,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1516,PSIVISSIG0002_1516,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,502,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1517,PSIVISSIG0002_1517,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1518,PSIVISSIG0002_1518,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,483,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1519,PSIVISSIG0002_1519,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1520,PSIVISSIG0002_1520,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,567,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1521,PSIVISSIG0002_1521,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1522,PSIVISSIG0002_1522,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,817,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1523,PSIVISSIG0002_1523,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1524,PSIVISSIG0002_1524,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1654,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1525,PSIVISSIG0002_1525,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,713,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1526,PSIVISSIG0002_1526,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1527,PSIVISSIG0002_1527,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1528,PSIVISSIG0002_1528,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,329,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1529,PSIVISSIG0002_1529,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1552,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1530,PSIVISSIG0002_1530,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1245,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1531,PSIVISSIG0002_1531,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1517,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1532,PSIVISSIG0002_1532,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1533,PSIVISSIG0002_1533,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1624,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1534,PSIVISSIG0002_1534,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,125,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1535,PSIVISSIG0002_1535,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1536,PSIVISSIG0002_1536,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,354,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1537,PSIVISSIG0002_1537,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1538,PSIVISSIG0002_1538,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1539,PSIVISSIG0002_1539,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,669,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1540,PSIVISSIG0002_1540,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1541,PSIVISSIG0002_1541,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1542,PSIVISSIG0002_1542,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,143,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1543,PSIVISSIG0002_1543,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1544,PSIVISSIG0002_1544,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1369,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1545,PSIVISSIG0002_1545,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1308,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1546,PSIVISSIG0002_1546,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1518,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1547,PSIVISSIG0002_1547,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,83,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1548,PSIVISSIG0002_1548,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1528,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1549,PSIVISSIG0002_1549,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1550,PSIVISSIG0002_1550,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1551,PSIVISSIG0002_1551,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1552,PSIVISSIG0002_1552,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1553,PSIVISSIG0002_1553,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1635,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1554,PSIVISSIG0002_1554,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,264,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1555,PSIVISSIG0002_1555,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1556,PSIVISSIG0002_1556,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1557,PSIVISSIG0002_1557,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,886,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1558,PSIVISSIG0002_1558,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1559,PSIVISSIG0002_1559,54,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,147,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1560,PSIVISSIG0002_1560,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,485,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1561,PSIVISSIG0002_1561,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1562,PSIVISSIG0002_1562,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1563,PSIVISSIG0002_1563,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1564,PSIVISSIG0002_1564,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1637,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1565,PSIVISSIG0002_1565,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,644,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1566,PSIVISSIG0002_1566,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1567,PSIVISSIG0002_1567,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,491,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1568,PSIVISSIG0002_1568,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1569,PSIVISSIG0002_1569,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1210,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1570,PSIVISSIG0002_1570,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,292,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1571,PSIVISSIG0002_1571,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1572,PSIVISSIG0002_1572,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1573,PSIVISSIG0002_1573,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1574,PSIVISSIG0002_1574,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,668,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1575,PSIVISSIG0002_1575,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1502,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1576,PSIVISSIG0002_1576,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1577,PSIVISSIG0002_1577,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1052,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1578,PSIVISSIG0002_1578,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1579,PSIVISSIG0002_1579,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1580,PSIVISSIG0002_1580,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,688,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1581,PSIVISSIG0002_1581,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1582,PSIVISSIG0002_1582,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1770,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1583,PSIVISSIG0002_1583,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1584,PSIVISSIG0002_1584,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1585,PSIVISSIG0002_1585,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,207,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1586,PSIVISSIG0002_1586,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1587,PSIVISSIG0002_1587,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,332,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1588,PSIVISSIG0002_1588,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1401,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1589,PSIVISSIG0002_1589,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1590,PSIVISSIG0002_1590,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1591,PSIVISSIG0002_1591,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,669,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1592,PSIVISSIG0002_1592,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,657,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1593,PSIVISSIG0002_1593,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1594,PSIVISSIG0002_1594,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,77,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1595,PSIVISSIG0002_1595,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,280,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1596,PSIVISSIG0002_1596,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1597,PSIVISSIG0002_1597,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1598,PSIVISSIG0002_1598,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1599,PSIVISSIG0002_1599,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1330,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1600,PSIVISSIG0002_1600,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,20,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1601,PSIVISSIG0002_1601,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1602,PSIVISSIG0002_1602,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,578,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1603,PSIVISSIG0002_1603,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,258,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1604,PSIVISSIG0002_1604,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,340,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1605,PSIVISSIG0002_1605,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1606,PSIVISSIG0002_1606,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1607,PSIVISSIG0002_1607,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,772,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1608,PSIVISSIG0002_1608,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1609,PSIVISSIG0002_1609,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1632,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1610,PSIVISSIG0002_1610,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1611,PSIVISSIG0002_1611,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1612,PSIVISSIG0002_1612,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,20,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1613,PSIVISSIG0002_1613,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,49,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1614,PSIVISSIG0002_1614,21,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,313,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1615,PSIVISSIG0002_1615,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1616,PSIVISSIG0002_1616,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1617,PSIVISSIG0002_1617,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1618,PSIVISSIG0002_1618,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,431,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1619,PSIVISSIG0002_1619,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,686,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1620,PSIVISSIG0002_1620,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,609,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1621,PSIVISSIG0002_1621,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1666,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1622,PSIVISSIG0002_1622,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,623,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1623,PSIVISSIG0002_1623,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,244,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1624,PSIVISSIG0002_1624,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1625,PSIVISSIG0002_1625,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1626,PSIVISSIG0002_1626,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1627,PSIVISSIG0002_1627,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1628,PSIVISSIG0002_1628,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,396,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1629,PSIVISSIG0002_1629,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1630,PSIVISSIG0002_1630,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,89,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1631,PSIVISSIG0002_1631,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1632,PSIVISSIG0002_1632,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1633,PSIVISSIG0002_1633,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1634,PSIVISSIG0002_1634,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,629,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1635,PSIVISSIG0002_1635,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1636,PSIVISSIG0002_1636,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,233,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1637,PSIVISSIG0002_1637,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1638,PSIVISSIG0002_1638,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1714,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1639,PSIVISSIG0002_1639,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1640,PSIVISSIG0002_1640,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1641,PSIVISSIG0002_1641,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,63,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1642,PSIVISSIG0002_1642,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1643,PSIVISSIG0002_1643,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,785,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1644,PSIVISSIG0002_1644,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,852,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1645,PSIVISSIG0002_1645,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1646,PSIVISSIG0002_1646,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1647,PSIVISSIG0002_1647,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,440,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1648,PSIVISSIG0002_1648,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1674,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1649,PSIVISSIG0002_1649,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,573,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1650,PSIVISSIG0002_1650,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1651,PSIVISSIG0002_1651,67,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,416,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1652,PSIVISSIG0002_1652,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1653,PSIVISSIG0002_1653,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1654,PSIVISSIG0002_1654,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,55,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1655,PSIVISSIG0002_1655,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1141,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1656,PSIVISSIG0002_1656,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1657,PSIVISSIG0002_1657,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1658,PSIVISSIG0002_1658,36,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1659,PSIVISSIG0002_1659,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1707,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1660,PSIVISSIG0002_1660,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1661,PSIVISSIG0002_1661,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,439,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1662,PSIVISSIG0002_1662,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,40,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1663,PSIVISSIG0002_1663,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,818,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1664,PSIVISSIG0002_1664,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1525,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1665,PSIVISSIG0002_1665,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1171,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1666,PSIVISSIG0002_1666,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1667,PSIVISSIG0002_1667,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,704,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1668,PSIVISSIG0002_1668,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,868,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1669,PSIVISSIG0002_1669,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,832,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1670,PSIVISSIG0002_1670,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,189,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1671,PSIVISSIG0002_1671,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,423,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1672,PSIVISSIG0002_1672,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,175,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1673,PSIVISSIG0002_1673,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,288,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1674,PSIVISSIG0002_1674,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1675,PSIVISSIG0002_1675,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,150,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1676,PSIVISSIG0002_1676,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,220,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1677,PSIVISSIG0002_1677,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1678,PSIVISSIG0002_1678,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,716,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1679,PSIVISSIG0002_1679,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,49,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1680,PSIVISSIG0002_1680,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,718,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1681,PSIVISSIG0002_1681,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,466,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1682,PSIVISSIG0002_1682,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1498,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1683,PSIVISSIG0002_1683,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1684,PSIVISSIG0002_1684,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1645,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1685,PSIVISSIG0002_1685,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1387,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1686,PSIVISSIG0002_1686,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,586,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1687,PSIVISSIG0002_1687,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1688,PSIVISSIG0002_1688,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,94,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1689,PSIVISSIG0002_1689,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,901,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1690,PSIVISSIG0002_1690,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1691,PSIVISSIG0002_1691,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,998,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1692,PSIVISSIG0002_1692,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1693,PSIVISSIG0002_1693,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,982,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1694,PSIVISSIG0002_1694,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,112,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1695,PSIVISSIG0002_1695,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1696,PSIVISSIG0002_1696,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1697,PSIVISSIG0002_1697,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1698,PSIVISSIG0002_1698,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,673,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1699,PSIVISSIG0002_1699,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1200,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1700,PSIVISSIG0002_1700,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,456,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1701,PSIVISSIG0002_1701,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,37,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1702,PSIVISSIG0002_1702,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1703,PSIVISSIG0002_1703,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,957,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1704,PSIVISSIG0002_1704,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1494,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1705,PSIVISSIG0002_1705,47,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,16,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1706,PSIVISSIG0002_1706,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1707,PSIVISSIG0002_1707,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,810,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1708,PSIVISSIG0002_1708,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,501,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1709,PSIVISSIG0002_1709,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1710,PSIVISSIG0002_1710,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1711,PSIVISSIG0002_1711,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,591,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1712,PSIVISSIG0002_1712,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1713,PSIVISSIG0002_1713,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,935,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1714,PSIVISSIG0002_1714,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,874,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1715,PSIVISSIG0002_1715,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1096,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1716,PSIVISSIG0002_1716,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,416,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1717,PSIVISSIG0002_1717,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,903,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1718,PSIVISSIG0002_1718,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1709,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1719,PSIVISSIG0002_1719,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1720,PSIVISSIG0002_1720,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1273,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1721,PSIVISSIG0002_1721,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,658,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1722,PSIVISSIG0002_1722,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,136,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1723,PSIVISSIG0002_1723,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,179,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1724,PSIVISSIG0002_1724,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1725,PSIVISSIG0002_1725,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,49,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1726,PSIVISSIG0002_1726,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,415,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1727,PSIVISSIG0002_1727,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1728,PSIVISSIG0002_1728,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1729,PSIVISSIG0002_1729,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,856,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1730,PSIVISSIG0002_1730,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1731,PSIVISSIG0002_1731,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,477,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1732,PSIVISSIG0002_1732,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1733,PSIVISSIG0002_1733,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1214,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1734,PSIVISSIG0002_1734,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1735,PSIVISSIG0002_1735,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,430,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1736,PSIVISSIG0002_1736,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,267,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1737,PSIVISSIG0002_1737,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1738,PSIVISSIG0002_1738,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1739,PSIVISSIG0002_1739,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,134,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1740,PSIVISSIG0002_1740,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1741,PSIVISSIG0002_1741,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1742,PSIVISSIG0002_1742,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1305,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1743,PSIVISSIG0002_1743,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1744,PSIVISSIG0002_1744,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,24,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1745,PSIVISSIG0002_1745,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1746,PSIVISSIG0002_1746,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1747,PSIVISSIG0002_1747,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1748,PSIVISSIG0002_1748,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1749,PSIVISSIG0002_1749,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1197,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1750,PSIVISSIG0002_1750,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1751,PSIVISSIG0002_1751,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,2,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1752,PSIVISSIG0002_1752,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1753,PSIVISSIG0002_1753,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1754,PSIVISSIG0002_1754,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1755,PSIVISSIG0002_1755,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,212,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1756,PSIVISSIG0002_1756,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1757,PSIVISSIG0002_1757,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1758,PSIVISSIG0002_1758,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1454,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1759,PSIVISSIG0002_1759,26,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1760,PSIVISSIG0002_1760,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,347,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1761,PSIVISSIG0002_1761,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,35,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1762,PSIVISSIG0002_1762,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1763,PSIVISSIG0002_1763,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1764,PSIVISSIG0002_1764,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,173,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1765,PSIVISSIG0002_1765,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1408,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1766,PSIVISSIG0002_1766,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,634,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1767,PSIVISSIG0002_1767,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1768,PSIVISSIG0002_1768,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1769,PSIVISSIG0002_1769,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1770,PSIVISSIG0002_1770,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1771,PSIVISSIG0002_1771,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1772,PSIVISSIG0002_1772,65,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1773,PSIVISSIG0002_1773,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1774,PSIVISSIG0002_1774,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1143,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1775,PSIVISSIG0002_1775,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1776,PSIVISSIG0002_1776,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1777,PSIVISSIG0002_1777,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1269,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1778,PSIVISSIG0002_1778,25,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1779,PSIVISSIG0002_1779,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1780,PSIVISSIG0002_1780,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1616,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1781,PSIVISSIG0002_1781,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,555,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1782,PSIVISSIG0002_1782,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1783,PSIVISSIG0002_1783,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1784,PSIVISSIG0002_1784,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1785,PSIVISSIG0002_1785,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1786,PSIVISSIG0002_1786,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1551,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1787,PSIVISSIG0002_1787,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1788,PSIVISSIG0002_1788,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,900,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1789,PSIVISSIG0002_1789,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1790,PSIVISSIG0002_1790,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1791,PSIVISSIG0002_1791,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1792,PSIVISSIG0002_1792,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,753,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1793,PSIVISSIG0002_1793,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,582,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1794,PSIVISSIG0002_1794,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1795,PSIVISSIG0002_1795,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1270,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1796,PSIVISSIG0002_1796,62,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,132,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1797,PSIVISSIG0002_1797,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1798,PSIVISSIG0002_1798,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1799,PSIVISSIG0002_1799,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,567,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1800,PSIVISSIG0002_1800,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,104,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1801,PSIVISSIG0002_1801,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1802,PSIVISSIG0002_1802,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,443,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1803,PSIVISSIG0002_1803,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1804,PSIVISSIG0002_1804,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1805,PSIVISSIG0002_1805,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1235,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1806,PSIVISSIG0002_1806,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1414,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1807,PSIVISSIG0002_1807,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,663,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1808,PSIVISSIG0002_1808,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1658,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1809,PSIVISSIG0002_1809,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,620,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1810,PSIVISSIG0002_1810,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1730,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1811,PSIVISSIG0002_1811,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1812,PSIVISSIG0002_1812,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1813,PSIVISSIG0002_1813,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,54,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1814,PSIVISSIG0002_1814,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,805,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1815,PSIVISSIG0002_1815,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,99,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1816,PSIVISSIG0002_1816,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1817,PSIVISSIG0002_1817,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,476,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1818,PSIVISSIG0002_1818,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1819,PSIVISSIG0002_1819,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1820,PSIVISSIG0002_1820,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1187,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1821,PSIVISSIG0002_1821,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,218,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1822,PSIVISSIG0002_1822,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,899,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1823,PSIVISSIG0002_1823,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1824,PSIVISSIG0002_1824,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1825,PSIVISSIG0002_1825,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,58,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1826,PSIVISSIG0002_1826,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1827,PSIVISSIG0002_1827,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,108,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1828,PSIVISSIG0002_1828,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,320,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1829,PSIVISSIG0002_1829,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1830,PSIVISSIG0002_1830,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1831,PSIVISSIG0002_1831,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1832,PSIVISSIG0002_1832,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,510,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1833,PSIVISSIG0002_1833,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1834,PSIVISSIG0002_1834,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,151,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1835,PSIVISSIG0002_1835,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,531,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1836,PSIVISSIG0002_1836,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1221,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1837,PSIVISSIG0002_1837,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1838,PSIVISSIG0002_1838,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,442,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1839,PSIVISSIG0002_1839,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1231,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1840,PSIVISSIG0002_1840,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1841,PSIVISSIG0002_1841,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1842,PSIVISSIG0002_1842,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1158,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1843,PSIVISSIG0002_1843,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1844,PSIVISSIG0002_1844,48,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,251,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1845,PSIVISSIG0002_1845,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1846,PSIVISSIG0002_1846,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1728,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1847,PSIVISSIG0002_1847,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,450,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1848,PSIVISSIG0002_1848,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1849,PSIVISSIG0002_1849,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,638,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1850,PSIVISSIG0002_1850,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1354,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1851,PSIVISSIG0002_1851,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1852,PSIVISSIG0002_1852,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1853,PSIVISSIG0002_1853,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,509,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1854,PSIVISSIG0002_1854,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,450,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1855,PSIVISSIG0002_1855,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,258,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1856,PSIVISSIG0002_1856,29,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,865,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1857,PSIVISSIG0002_1857,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1362,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1858,PSIVISSIG0002_1858,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,703,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1859,PSIVISSIG0002_1859,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,515,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1860,PSIVISSIG0002_1860,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,89,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1861,PSIVISSIG0002_1861,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,267,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1862,PSIVISSIG0002_1862,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1863,PSIVISSIG0002_1863,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1864,PSIVISSIG0002_1864,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1865,PSIVISSIG0002_1865,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,405,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1866,PSIVISSIG0002_1866,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,896,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1867,PSIVISSIG0002_1867,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1070,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1868,PSIVISSIG0002_1868,64,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1869,PSIVISSIG0002_1869,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,370,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1870,PSIVISSIG0002_1870,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1642,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1871,PSIVISSIG0002_1871,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1872,PSIVISSIG0002_1872,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,644,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1873,PSIVISSIG0002_1873,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1874,PSIVISSIG0002_1874,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,361,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1875,PSIVISSIG0002_1875,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1061,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1876,PSIVISSIG0002_1876,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,188,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1877,PSIVISSIG0002_1877,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,478,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1878,PSIVISSIG0002_1878,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1879,PSIVISSIG0002_1879,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,952,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1880,PSIVISSIG0002_1880,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,585,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1881,PSIVISSIG0002_1881,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,348,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1882,PSIVISSIG0002_1882,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1883,PSIVISSIG0002_1883,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1884,PSIVISSIG0002_1884,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,619,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1885,PSIVISSIG0002_1885,61,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1886,PSIVISSIG0002_1886,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,273,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1887,PSIVISSIG0002_1887,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,624,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1888,PSIVISSIG0002_1888,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1889,PSIVISSIG0002_1889,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,62,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1890,PSIVISSIG0002_1890,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1891,PSIVISSIG0002_1891,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1097,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1892,PSIVISSIG0002_1892,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1893,PSIVISSIG0002_1893,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,82,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1894,PSIVISSIG0002_1894,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1389,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1895,PSIVISSIG0002_1895,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1896,PSIVISSIG0002_1896,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1419,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1897,PSIVISSIG0002_1897,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,38,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1898,PSIVISSIG0002_1898,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,51,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1899,PSIVISSIG0002_1899,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,927,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1900,PSIVISSIG0002_1900,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,796,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1901,PSIVISSIG0002_1901,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1562,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1902,PSIVISSIG0002_1902,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,928,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1903,PSIVISSIG0002_1903,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1611,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1904,PSIVISSIG0002_1904,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1905,PSIVISSIG0002_1905,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1906,PSIVISSIG0002_1906,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1907,PSIVISSIG0002_1907,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,788,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1908,PSIVISSIG0002_1908,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1909,PSIVISSIG0002_1909,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,969,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1910,PSIVISSIG0002_1910,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1911,PSIVISSIG0002_1911,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,50,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1912,PSIVISSIG0002_1912,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1913,PSIVISSIG0002_1913,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1914,PSIVISSIG0002_1914,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1915,PSIVISSIG0002_1915,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,568,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1916,PSIVISSIG0002_1916,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,566,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1917,PSIVISSIG0002_1917,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1137,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1918,PSIVISSIG0002_1918,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1586,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1919,PSIVISSIG0002_1919,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1920,PSIVISSIG0002_1920,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,187,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1921,PSIVISSIG0002_1921,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,710,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1922,PSIVISSIG0002_1922,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1923,PSIVISSIG0002_1923,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1924,PSIVISSIG0002_1924,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1574,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1925,PSIVISSIG0002_1925,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1926,PSIVISSIG0002_1926,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1927,PSIVISSIG0002_1927,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1421,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1928,PSIVISSIG0002_1928,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,369,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1929,PSIVISSIG0002_1929,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1930,PSIVISSIG0002_1930,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1931,PSIVISSIG0002_1931,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1932,PSIVISSIG0002_1932,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1933,PSIVISSIG0002_1933,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,894,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1934,PSIVISSIG0002_1934,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,201,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1935,PSIVISSIG0002_1935,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1936,PSIVISSIG0002_1936,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1152,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1937,PSIVISSIG0002_1937,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,692,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1938,PSIVISSIG0002_1938,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1939,PSIVISSIG0002_1939,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,690,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1940,PSIVISSIG0002_1940,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1166,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1941,PSIVISSIG0002_1941,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,433,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1942,PSIVISSIG0002_1942,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,647,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1943,PSIVISSIG0002_1943,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1027,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1944,PSIVISSIG0002_1944,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,348,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1945,PSIVISSIG0002_1945,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,935,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1946,PSIVISSIG0002_1946,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1947,PSIVISSIG0002_1947,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,872,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1948,PSIVISSIG0002_1948,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1058,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1949,PSIVISSIG0002_1949,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1486,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1950,PSIVISSIG0002_1950,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,965,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1951,PSIVISSIG0002_1951,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1952,PSIVISSIG0002_1952,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1244,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1953,PSIVISSIG0002_1953,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1954,PSIVISSIG0002_1954,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1115,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1955,PSIVISSIG0002_1955,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1956,PSIVISSIG0002_1956,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1957,PSIVISSIG0002_1957,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,441,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1958,PSIVISSIG0002_1958,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1959,PSIVISSIG0002_1959,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1679,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1960,PSIVISSIG0002_1960,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1961,PSIVISSIG0002_1961,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1534,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1962,PSIVISSIG0002_1962,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1963,PSIVISSIG0002_1963,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,325,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1964,PSIVISSIG0002_1964,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,758,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1965,PSIVISSIG0002_1965,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1966,PSIVISSIG0002_1966,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1967,PSIVISSIG0002_1967,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,22,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1968,PSIVISSIG0002_1968,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1036,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1969,PSIVISSIG0002_1969,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1406,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1970,PSIVISSIG0002_1970,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,395,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1971,PSIVISSIG0002_1971,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1541,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1972,PSIVISSIG0002_1972,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1973,PSIVISSIG0002_1973,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,553,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1974,PSIVISSIG0002_1974,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1975,PSIVISSIG0002_1975,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,995,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1976,PSIVISSIG0002_1976,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1977,PSIVISSIG0002_1977,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,301,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1978,PSIVISSIG0002_1978,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1979,PSIVISSIG0002_1979,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1980,PSIVISSIG0002_1980,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1064,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1981,PSIVISSIG0002_1981,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,377,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1982,PSIVISSIG0002_1982,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,76,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1983,PSIVISSIG0002_1983,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,134,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1984,PSIVISSIG0002_1984,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1138,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1985,PSIVISSIG0002_1985,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1986,PSIVISSIG0002_1986,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1310,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1987,PSIVISSIG0002_1987,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,425,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1988,PSIVISSIG0002_1988,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1989,PSIVISSIG0002_1989,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,108,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1990,PSIVISSIG0002_1990,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1991,PSIVISSIG0002_1991,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1992,PSIVISSIG0002_1992,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,944,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1993,PSIVISSIG0002_1993,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,697,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1994,PSIVISSIG0002_1994,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,437,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1995,PSIVISSIG0002_1995,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1996,PSIVISSIG0002_1996,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1997,PSIVISSIG0002_1997,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,904,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1998,PSIVISSIG0002_1998,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,985,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1999,PSIVISSIG0002_1999,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2000,PSIVISSIG0002_2000,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2001,PSIVISSIG0002_2001,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2002,PSIVISSIG0002_2002,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2003,PSIVISSIG0002_2003,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,518,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2004,PSIVISSIG0002_2004,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1076,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2005,PSIVISSIG0002_2005,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2006,PSIVISSIG0002_2006,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2007,PSIVISSIG0002_2007,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2008,PSIVISSIG0002_2008,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1056,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2009,PSIVISSIG0002_2009,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,991,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2010,PSIVISSIG0002_2010,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2011,PSIVISSIG0002_2011,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,389,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2012,PSIVISSIG0002_2012,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1490,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2013,PSIVISSIG0002_2013,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2014,PSIVISSIG0002_2014,32,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,537,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2015,PSIVISSIG0002_2015,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2016,PSIVISSIG0002_2016,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,520,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2017,PSIVISSIG0002_2017,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2018,PSIVISSIG0002_2018,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2019,PSIVISSIG0002_2019,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,303,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2020,PSIVISSIG0002_2020,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2021,PSIVISSIG0002_2021,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,985,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2022,PSIVISSIG0002_2022,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1085,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2023,PSIVISSIG0002_2023,23,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1175,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2024,PSIVISSIG0002_2024,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2025,PSIVISSIG0002_2025,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,483,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2026,PSIVISSIG0002_2026,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2027,PSIVISSIG0002_2027,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,468,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2028,PSIVISSIG0002_2028,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1521,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2029,PSIVISSIG0002_2029,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2030,PSIVISSIG0002_2030,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1058,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2031,PSIVISSIG0002_2031,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,274,1,Censored at the last contact date,DEATH
PSIVISSIG0002,2032,PSIVISSIG0002_2032,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2033,PSIVISSIG0002_2033,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2034,PSIVISSIG0002_2034,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2035,PSIVISSIG0002_2035,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,925,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2036,PSIVISSIG0002_2036,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,573,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2037,PSIVISSIG0002_2037,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2038,PSIVISSIG0002_2038,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,495,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2039,PSIVISSIG0002_2039,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,472,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2040,PSIVISSIG0002_2040,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2041,PSIVISSIG0002_2041,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2042,PSIVISSIG0002_2042,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2043,PSIVISSIG0002_2043,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2044,PSIVISSIG0002_2044,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2045,PSIVISSIG0002_2045,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1732,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2046,PSIVISSIG0002_2046,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,672,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2047,PSIVISSIG0002_2047,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,252,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2048,PSIVISSIG0002_2048,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2049,PSIVISSIG0002_2049,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Censored at the last contact date,DEATH
PSIVISSIG0002,2050,PSIVISSIG0002_2050,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1660,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2051,PSIVISSIG0002_2051,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1217,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2052,PSIVISSIG0002_2052,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2053,PSIVISSIG0002_2053,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2054,PSIVISSIG0002_2054,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,350,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2055,PSIVISSIG0002_2055,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,Censored at the last contact date,DEATH
PSIVISSIG0002,2056,PSIVISSIG0002_2056,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2057,PSIVISSIG0002_2057,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2058,PSIVISSIG0002_2058,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,63,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2059,PSIVISSIG0002_2059,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2060,PSIVISSIG0002_2060,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,369,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2061,PSIVISSIG0002_2061,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,822,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2062,PSIVISSIG0002_2062,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1047,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2063,PSIVISSIG0002_2063,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2064,PSIVISSIG0002_2064,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2065,PSIVISSIG0002_2065,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,105,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2066,PSIVISSIG0002_2066,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2067,PSIVISSIG0002_2067,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2068,PSIVISSIG0002_2068,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2069,PSIVISSIG0002_2069,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2070,PSIVISSIG0002_2070,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2071,PSIVISSIG0002_2071,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,722,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2072,PSIVISSIG0002_2072,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,333,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2073,PSIVISSIG0002_2073,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,604,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2074,PSIVISSIG0002_2074,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2075,PSIVISSIG0002_2075,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,92,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2076,PSIVISSIG0002_2076,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2077,PSIVISSIG0002_2077,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,170,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2078,PSIVISSIG0002_2078,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,851,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2079,PSIVISSIG0002_2079,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2080,PSIVISSIG0002_2080,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,879,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2081,PSIVISSIG0002_2081,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,227,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2082,PSIVISSIG0002_2082,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,Censored at the last contact date,DEATH
PSIVISSIG0002,2083,PSIVISSIG0002_2083,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,880,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2084,PSIVISSIG0002_2084,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,183,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2085,PSIVISSIG0002_2085,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,211,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2086,PSIVISSIG0002_2086,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1750,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2087,PSIVISSIG0002_2087,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,12,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2088,PSIVISSIG0002_2088,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2089,PSIVISSIG0002_2089,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,897,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2090,PSIVISSIG0002_2090,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,657,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2091,PSIVISSIG0002_2091,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2092,PSIVISSIG0002_2092,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1776,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2093,PSIVISSIG0002_2093,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,622,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2094,PSIVISSIG0002_2094,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1436,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2095,PSIVISSIG0002_2095,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1271,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2096,PSIVISSIG0002_2096,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2097,PSIVISSIG0002_2097,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,448,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2098,PSIVISSIG0002_2098,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1597,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,2099,PSIVISSIG0002_2099,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2100,PSIVISSIG0002_2100,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2101,PSIVISSIG0002_2101,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
